The effect of N-acetylcysteine supplementation on recovery of strength following eccentric muscle injury by Luke, Ryan C
Georgia State University
ScholarWorks @ Georgia State University
Kinesiology Dissertations Department of Kinesiology and Health
Fall 12-13-2011
The effect of N-acetylcysteine supplementation on
recovery of strength following eccentric muscle
injury
Ryan C. Luke
Follow this and additional works at: https://scholarworks.gsu.edu/kin_health_diss
Part of the Kinesiology Commons
This Dissertation is brought to you for free and open access by the Department of Kinesiology and Health at ScholarWorks @ Georgia State University.
It has been accepted for inclusion in Kinesiology Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more
information, please contact scholarworks@gsu.edu.
Recommended Citation
Luke, Ryan C., "The effect of N-acetylcysteine supplementation on recovery of strength following eccentric muscle injury."
Dissertation, Georgia State University, 2011.
https://scholarworks.gsu.edu/kin_health_diss/8
  
ACCEPTANCE 
This dissertation, THE EFFECT OF N-ACETYLCYSTEINE SUPPLEMENTATION 
ON RECOVERY OF STRENGTH FOLLOWING ECCENTRIC MUSCLE INJURY, by 
RYAN C. LUKE, was prepared under the direction of the candidate’s Dissertation 
Advisory Committee.  It is accepted by the committee members in partial fulfillment of 
the requirements for the degree of Doctor of Philosophy in the College of Education, 
Georgia State University. 
The Dissertation Advisory Committee and the student’s Department Chair, as 
representatives of the faculty, certify that this dissertation has met all standards of 
excellence and scholarship as determined by the faculty.  The Dean of the College of 
Education concurs. 
 
 
 
______________________________  ______________________________ 
J. Andrew Doyle, Ph.D.    Jeffrey C. Rupp, Ph.D. 
Committee Chair     Committee Member 
 
 
 
______________________________  ______________________________ 
Christopher P. Ingalls, Ph.D.    Dan Benardot, Ph.D. 
Committee Member     Committee Member 
 
 
 
______________________________ 
Date 
 
 
 
______________________________ 
Jacalyn L. Lund 
Chair, Department of Kinesiology and Health 
 
 
 
______________________________ 
R.W. Kamphaus, Ph.D. 
Dean and Distinguished Research Professor 
College of Education 
  
AUTHOR’S STATEMENT 
By presenting this dissertation as a partial fulfillment of the requirements for the 
advanced degree from Georgia State University, I agree that the library of Georgia State 
University shall make it available for inspection and circulation in accordance with its 
regulations governing materials of this type.  I agree that permission to quote, to copy 
from, or to publish this dissertation may be granted by the professor under whose 
direction it was written, by the College of Education’s director of graduate studies and 
research, or by me.  Such quoting, copying, or publishing must be solely for scholarly 
purposes and will not involve potential financial gain.  It is understood that any copying 
from or publication of this dissertation which involves potential financial gain will not be 
allowed without my written permission. 
 
 
 
_______________________________________________ 
Ryan C. Luke 
 
 
  
NOTICE TO BORROWERS  
All dissertations deposited in the Georgia State University library must be used in 
accordance with the stipulations prescribed by the author in the preceding statement. The 
author of this dissertation is: 
Ryan Charles Luke 
19 Hilliard St. SE Apt. 2 
Atlanta, GA 30312 
 
The director of this dissertation is: 
 
Dr. J. Andrew Doyle 
Department of Kinesiology and Health 
College of Education 
Georgia State University 
Atlanta, GA 30303 - 3083 
 
 
 
 
 
 
 
 
 
 
  
VITA 
 
Ryan Charles Luke 
 
ADDRESS: 19 Hilliard St. SE Apt. 2 
  Atlanta, GA 30312 
   
EDUCATION: 
Ph.D. 2011  Georgia State University 
     Kinesiology 
M.A. 2005  California State University, Fresno 
     Kinesiology 
B.S.E. 2002  University of Kansas 
     Education 
 
PROFESSIONAL EXPERIENCE: 
  2007 – Present Graduate Research Assistant 
     Department of Kinesiology and Health 
     Georgia State University, Atlanta, GA 
  2005 – 2007  Adjunct Faculty 
     Department of Kinesiology 
     California State University, Fresno, Fresno, CA 
  2003 – 2005  Graduate Teaching Assistant 
     Department of Kinesiology 
     California State University, Fresno, Fresno, CA 
 
PROFESSIONAL SOCIETIES AND ORGANIZATIONS: 
2009 – Present Member, American Physiological Society 
2003 – Present Member, American College of Sports Medicine 
2002 – Present Member, National Strength & Conditioning 
Association 
2002 – 2007   Member, USA Weightlifting    
 
PUBLISHED PAPERS: 
 Corona, B.T., Balog E.R., Doyle, J.A., Rupp, J.R., Luke, R.C., Ingalls, C.P. 
Junctophilin Damage Contributes to Early Strength Deficits and EC Coupling Failure 
After Eccentric Contractions.  American Journal of Physiology – Cell Physiology. 
298(2): C365-76, February 2010. 
 
PUBLISHED ABSTRACTS: 
 Luke, R.C., Coles, M.G., Anderson, T.A. A Comparison of the Results of an 
Annual Fit-For-Duty Testing Program for Police Officers and Firefighters. Medicine & 
Science in Sports & Exercise. 38(5) Supplement:S513, May 2006. 
  
 
  
Coles, M.G., Anderson, T.A , Morales, J.O., Ellis, P.M., Luke, R.C. Fitness 
Profiles of Novice to Elite Athletes Participating in the 14th Annual Pole Vault Summit. 
Medicine & Science in Sports & Exercise. 38(5) Supplement:S232, May 2006. 
Luke, R.C., Coles, M.G., Anderson, T.A., Gilbert, J.N.  Oxygen cost and heart 
rate response during interactive whole body video gaming. Medicine & Science in Sports 
& Exercise. 37(5) Supplement:S329, May 2005. 
 
PRESENTATIONS: 
Luke, R.C., Coles, M.G., Anderson, T.A. A Comparison of the Results of an 
Annual Fit-For-Duty Testing Program for Police Officers and Firefighters. Paper 
presented at the 2006 annual national meeting of the American College of Sports 
Medicine, Denver, CO. 
Coles, M.G., Anderson, T.A , Morales, J.O., Ellis, P.M., Luke, R.C. Fitness 
Profiles of Novice to Elite Athletes Participating in the 14th Annual Pole Vault Summit. 
Paper presented at the 2006 annual meeting of the American College of Sports Medicine, 
Denver, CO. 
Luke, R.C. Video Games and Fitness:  A New Frontier. Presentation at the 2006 
Annual Conference of California Association for Health, Physical Education, Recreation 
and Dance. 
 Luke, R.C., Coles, M.G., Anderson, T.A., Gilbert, J.N.  Oxygen cost and heart 
rate response during interactive whole body video gaming. .  Paper presented at the 2005 
annual national meeting of the American College of Sports Medicine, Nashville, TN. 
 
GRANTS: 
Gatorade Sports Science Institute:  Student Grant; $3,500.  September, 2010. 
 
 
 
  
ABSTRACT 
 
 
THE EFFECT OF N-ACETYLCYSTEINE SUPPLEMENTATION ON  
RECOVERY OF STRENGTH FOLLOWING  
ECCENTRIC MUSCLE INJURY 
by 
Ryan C. Luke 
 
This study determined the effect of N-acetylcysteine (NAC) supplementation on recovery 
of strength following eccentric muscle injury. Female subjects (n = 21, age = 20.7 ± .10 
yr, weight = 68.05 ± 10.3 kg, height = 1.69 ± .07 m) performed one bout of eccentric 
exercise involving the forearm flexor muscles. Subjects were given a placebo (food-grade 
cellulose; n = 10) or NAC supplement (10 mg·kg-1 bw·d-1; n = 11) for 7D prior to and 
14D following the exercise bout. Maximal Voluntary Contraction (MVC) torque, muscle 
soreness, range of motion (ROM), and arm circumference were measured at pre-exercise, 
immediately post-exercise, and at 1D, 3D, 7D and 10D post-exercise.  In addition, serum 
interleukin-6 (IL-6), serum creatine kinase (CK), and serum glutathione were measured.  
Subjects also completed a food frequency questionnaire to determine the antioxidant 
content of their diet. There was no difference in the loss and subsequent recovery of 
muscular strength between the placebo and NAC group immediately post-exercise (26.93 
± 6.4 vs. 24.95 ±9.4 Nm), 1D (27.83 ± 5.7 vs. 26.9 ± 8.5 Nm), 3D (38.35 ± 6.7 vs. 34.69 
± 10.2 Nm), 7D (46.9 ± 8.8 vs. 42.5 ± 11.8 Nm), or 10D (57.83 ± 11.7 vs. 52.92 ± 14.3 
Nm) post-exercise (p = .274).  In addition, there was no difference in muscle soreness (p 
= .752), arm circumference (p = .535), ROM (p = .539), serum CK (p = .449), serum 
glutathione (p = .967), or serum IL-6 (p = .360) at any time point.  Scores on the food 
frequency questionnaire demonstrated that dietary antioxidant intake was not different 
between groups (41.04 ± 8.04 vs. 33.01 ± 12.6; p = .054).  In conclusion, a bout of 
  
eccentric forearm flexor exercise resulted in muscle injury and a significant decrease in 
subjects’ ability to produce force. Supplementation with NAC had no effect on recovery 
of strength, arm circumference, ROM, serum CK, serum IL-6, or serum glutathione at 
any time point following the exercise bout.  These results demonstrate that NAC has no 
effect on recovery of strength following eccentric muscle injury. 
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CHAPTER 1 
THE EFFECT OF N-ACETYLCYSTEINE SUPPLEMENTATION ON RECOVERY 
OF STRENGTH FOLLOWING ECCENTRIC MUSCLE INJURY 
Introduction 
Exercise induced muscle damage is regularly observed in individuals following 
novel or unaccustomed exercise involving eccentric muscle contractions (1).  This type of 
muscle damage is associated with increased muscle soreness and swelling, increased 
intramuscular proteins in the bloodstream, and significant (but temporary) decrements in 
MVC torque (2).  The decrease in MVC torque can persist for time periods up to (and in 
some cases, exceeding) one month (3).  
Recovery and regeneration following eccentric muscle injury adheres to a fairly 
predictable timeline.  The entire process is best characterized by a model describing four 
different stages of injury and subsequent recovery and regeneration; (1) intial, (2) 
autogenic, (3) phagocytic, and (4) regenerative (4). 
The muscle injury process is augmented or magnified by the production of 
reactive oxygen species (ROS).  Overproduction of ROS may overwhelm the body’s 
endogenous antioxidant defense mechanisms and lead to oxidant stress.  This oxidant 
stress may result in further (e.g., “secondary”) damage to the muscle following the initial 
mechanical insult.  Antioxidant supplementation has been purported to increase the 
body’s ability to scavenge free radicals and combat production of ROS following 
exercise-induced muscle injury. 
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The desire to speed the process of recovery from muscle injury or reduce the 
symptoms of soreness, swelling, and/or decrements in MVC torque have led some 
researchers to investigate the effects of supplementation with antioxidants on symptoms 
of exercise-induced muscle damage (5, 6).  However the results of these studies have 
been equivocal (5, 7).  
Exercise-Induced Muscle Damage 
Causes 
Exercise induced muscle damage is a common occurrence and can be the 
consequence of a broad range of activities (8-10). This type of muscle damage is 
particularly associated with events requiring the performance of eccentric muscle 
contractions (1, 11). Eccentric muscle contractions occur when a contracting muscle is 
forcibly lengthened.  These types of contractions take place when an individual 
endeavors to stop or slow their body or a segment of their body when it is already in 
motion (e.g., lowering a barbell during a barbell biceps curl).  In contrast, a concentric 
contraction occurs when a contracting muscle shortens while developing tension and an 
isometric contraction occurs when a muscle remains at the same length while developing 
tension which can cause injury (12).  All of these muscle actions are components of daily 
movement.  However, previous studies have demonstrated that when compared with 
repetitive execution of concentric and isometric contractions, repetitive execution of 
eccentric muscle contractions will result in significantly greater muscle damage (11, 13-
15).   
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The high forces associated with eccentric muscle contractions make them 
particularly injurious. Force production during eccentric contractions can be 80-100% 
higher than forces produced during isometric or concentric muscle contractions (3).  This 
type of muscle action is associated with higher forces because the external force applied 
can overcome the ability of the muscle to resist that force (16).  As a result, the 
contracting muscle is forced to lengthen.  This lengthening occurs while additional 
tension is produced.  When a muscle is forced to lengthen at a slow velocity, tension can 
reach 125% of maximal isometric tetanic force (16).  Although these contractions are 
associated with much higher forces, it is interesting to note that energy demands are 
lower and fewer motor units are recruited during eccentric muscle contractions (17).  
Therefore, during an eccentric muscle contraction, a smaller number of motor units 
(when compared to those active during concentric and isometric contractions) are 
exposed to significantly greater forces. 
Symptoms 
A decrease in force generating capability, as measured by MVC torque, is thought 
to the most accurate and reliable indicator of eccentric contraction-induced muscle 
damage because a reduction in MVC torque persists until the muscle returns to an 
undamaged state (18, 19). The magnitude of MVC torque loss following the injury 
protocol is dependant on the workload encountered during the injurious bout of exercise.  
If the load encountered during the eccentric contraction protocol is adequate, the 
immediate post-injury MVC torque deficits can be significant.  In humans, performance 
of two sets of 35 maximal eccentric contractions of the forearm flexors has been shown 
to result in immediate, post-injury isometric force deficits greater than 50%.  However, in 
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the same study a protocol of 24 maximal eccentric contractions was performed with the 
opposite limb.  This injury protocol resulted in much smaller changes in values for 
immediate post-injury MVC torque and MVC torque had fully recovered by 2 days post-
injury while the 70-contraction protocol experienced significantly greater reductions in 
MVC torque and had not completely recovered at 5 days post-injury (10). A large 
number of additional studies (human and animal) utilizing effective eccentric injury 
protocols have also demonstrated that performance of eccentric contraction protocols can 
result in post-injury isometric force deficits in excess of 40-50% when compared to pre-
injury isometric force measurements (14, 20-22). If the workload during the eccentric 
contraction protocol is great enough, the impaired function (e.g., MVC torque, isometric 
tetanic force) may persist for some time.  Depending on the severity of the injury, the 
time required for recovery to pre-injury MVC torque or isometric tetanic force levels can 
range from 10-14 days post-injury to 30 days post-injury for both animals and humans (3, 
14, 23).   
The muscle soreness experienced following eccentric muscle injury is termed 
Delayed Onset Muscle Soreness (DOMS).  This condition is the result of a grade one 
muscle strain injury resulting from small micro-tears in the muscle (24).  As its name 
would suggest, DOMS does not occur immediately following eccentric muscle injury. 
The temporal sequence of DOMS usually begins 6-12 hours post-exercise when the 
injury presents as tender or aching muscles that are apparent during palpation or 
movement (25).  Peak pain usually occurs between 48-72 hours post-injury and usually 
subsides 8-10 days post-injury (4, 14, 26).  There is a great deal of research examining 
DOMS but there is not a clear single mechanism that can be attributed to the onset and 
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persistence of pain following eccentric muscle injury (24).  Proposed mechanisms have 
included lactate accumulation (27), involuntary muscle spasms (28), connective tissue 
damage (29), muscle tissue damage (30), inflammation (31), and increased muscle 
temperature (32).  A common factor among these proposed mechanisms is the increased 
production of free radicals (24).  This commonality points to a possible reason for the 
attenuation of DOMS that has been associated with supplementation of antioxidants 
following eccentric muscle injury (33).  However, the precise nature of the relationship 
between free radical production and DOMS has not been determined. 
It has been suggested that swelling and edema are another possible cause of 
DOMS because of the potential for pain caused by increased muscular pressure.  
However, studies investigating this connection have found that the greatest swelling 
occurs when soreness is subsiding (14).  In addition, Newham & Jones (1987) did not 
find an increase in muscular pressure following eccentric muscle injury when DOMS was 
most apparent (34).  Measurement of muscular swelling is accomplished by comparing 
girth measurements of the injured muscle at different time points.  Human studies 
involving injury of the forearm flexors have found that swelling gradually develops in the 
days following eccentric muscle injury and peaks at five days post-injury (14). 
As previously stated, eccentric muscle injury results in an increase in 
intramuscular proteins in the bloodstream (35). For the purposes of this review, the focus 
will be on Creatine Kinase (CK) and Interleukin-6 (IL-6).  Previous studies have 
demonstrated that these proteins are following an acute bout of eccentric exercise (36-
38).   
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The most commonly studied of these proteins is CK.  Normal resting CK levels 
are typically between 50 and 250 U/L (34).  Muscle injury (especially eccentric 
contraction-induced muscle injury) can result in a dramatic rise in serum CK levels.  
Eccentric exercise of the forearm flexors has resulted in average post-injury CK levels of 
6,000 U/L (38); a 2,380-11,900% rise above baseline levels.  The CK response to 
eccentric exercise is clearly significant.  However, the magnitude of changes in CK are 
very poorly correlated with the magnitude of decreases in MVC torque.  Serum CK levels 
normally show a delayed response to eccentric muscle injury, peaking at 2-4 days post-
injury (14), while MVC torque (or isometric tetanic strength) values are immediately 
depressed.  In one study (n = 109) utilizing eccentric contraction-induced injury of the 
forearm flexors, CK levels peaked at 4 days post-injury when post-injury MVC torque 
was reduced by >50% (14).  In addition, Warren et al., (1999) calculated that the percent 
variance in MVC torque accounted for by variance in serum CK was only moderate (18).  
Further support for the dissociation between the variables of CK levels and MVC torque 
comes from studies examining the repeated bout effect.  These studies demonstrate an 
elimination of the increase in CK levels following eccentric muscle injury while the 
immediate decrements in MVC torque were nearly identical (34, 39).  
There is a large amount of inter-subject variability in the CK response (18).  The 
previously mentioned study by Nosaka et al., (1992) saw an average rise in CK levels 
from 60 U/L to 6,000 U/L.  However, the variability displayed between subjects was 
quite large with one subject presenting a CK level of 25,000 U/L.  This variability, when 
combined with the small sample sizes utilized by many studies, contributes to the relative 
unpredictability of the magnitude of the CK response following eccentric exercise for 
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individual subjects (14).  These findings suggest that caution should be used when 
interpreting results associated with serum CK response to eccentric contraction-induced 
muscle injury (18). 
Interleukin 6 was the first cytokine identified as a “myokine”; a cytokine 
produced from muscle (40).  It is primarily a pro-inflammatory cytokine that possesses 
some anti-inflammatory properties.  Interleukin 6 functions to increase muscle protein 
breakdown by reducing circulating levels of insulin-like growth factor 1 (IGF-1) while 
inducing myoblast proliferation and differentiation (41, 42). It is significantly elevated 
with eccentric contraction-induced muscle injury, and precedes the appearance of other 
cytokines in the circulation (43).   In fact, IL-6 seems to be the cytokine most consistently 
elevated in response to trauma.  During exercise, it is released into the circulation (can 
increase up to 100 fold) to promote liver glycogenolysis (44).  The size of the workload 
and the muscle mass involved during eccentric contraction-induced muscle injury seem 
to play a role in post-injury serum IL-6 levels.  In support of this assertion, Nosaka and 
Clarkson, (1996) had male subjects perform 24 maximal eccentric contractions of the 
biceps brachii and found no changes in serum IL-6 levels (45).  In contrast, Smith et al., 
(2000) had male subjects perform 4 sets (12 repetitions per set) of eccentric bench press 
and leg curl exercises at an intensity equivalent to 100% 1RM and found significant 
increases in IL-6 at 12, 24, and 72 hours after exercise (46).  Other works have clearly 
demonstrated the elevation of serum IL-6 following eccentric contraction-induced muscle 
injury.  However, when compared to prolonged exercise, eccentric contraction-induced 
muscle injury results in a delayed peak and a slower decrease of serum IL-6 during 
recovery (47).  It is also important to note that contracting skeletal muscle is the primary 
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source of serum IL-6 (48).  Therefore, it is not surprising that exercise involving a limited 
muscle mass (e.g., eccentric contraction-induced muscle injury of the forearm flexors) 
may be insufficient to increase plasma IL-6 above pre-exercise levels (45, 47). 
Mechanism 
It is commonly accepted that the higher forces associated with eccentric muscle 
contractions result in muscle damage. However, there is disagreement concerning the 
primary mechanism behind immediate post-injury signs of muscle damage (i.e., 
decreased contractile force). The presence of disrupted sarcomeres indicates that damage 
to force generating and force bearing structures may be responsible for the loss of force 
production (3, 49).  However, strength losses have been shown to be 2.5-7.6 times greater 
than histopathology results would suggest (3). Therefore, immediate post-injury force 
deficits cannot be completely or primarily responsible for initial force deficits.  It is most 
likely that initial decreases in force are primarily due to a disruption in excitation-
contraction (E-C) coupling, resulting in an inability to activate contractile proteins in the 
muscle tissue (3, 50).  The loss of force generating and force bearing structures accounts 
for a greater portion of the deficits in isometric strength as the recovery process 
progresses.  Strength deficits can be completely attributed to contractile protein loss by 
14 days post-injury (21, 51, 52). 
Although there is not complete agreement regarding the exact mechanism behind 
initial force deficits following eccentric muscle injury, it is commonly accepted that 
mechanical injury is the primary initiating event causing the immediate post-injury 
decline in force (26).  It is apparent that the degree of injury in muscle tissue is associated 
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with the tension produced during eccentric contractions, thus supporting the role of 
mechanical factors in the initial stages of muscle damage (4, 26, 53).  It also has been 
argued that the initiating event in eccentric muscle damage is metabolic in nature.  
However, the possibility of a metabolic contribution to the injury process during 
eccentric contractions seems unlikely due to the smaller energy demands of these muscle 
actions (17).   
The immediate/initial trauma associated with eccentric muscle contractions has 
been termed “microinjury”.  This term was adopted because the initial sites of injury are 
primarily sub-cellular and affect a relatively small percentage of the total number of 
fibers in the muscle (4).  However, during the time period immediately following muscle 
injury, further myofibrillar damage occurs. This damage is thought to be the result of a 
disruption in intracellular calcium homeostasis (1, 54-56).  A two-part model gives a 
simple picture of the phases of muscle damage; (1) the initial phase involving the major 
muscle damage that occurs during the exercise bout and (2) the secondary damage that 
occurs through processes associated with disruptions in calcium homeostasis and the 
ensuing inflammatory response (57).   
However, a different model of the overall response to eccentric muscle injury 
provides a more complete picture of muscle damage and subsequent recovery.  This 
model involves four distinct stages; the initial stage (1) includes the trauma-inducing 
event that activates the degenerative and regenerative phases in the injury and recovery 
processes.  The autogenic stage (2) lasts for 4-6 hours and immediately follows the 
injury-inducing event.  This stage is associated with an increase in activity of the 
indigenous proteolytic and lipolytic systems, resulting in an increase in degradation of 
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cellular structures within the muscle fiber.  The phagocytic stage (3) occurs from 4-6 
hours after injury and lasts for 2-4 days following injury.  It is marked by the 
manifestation of a distinctive inflammatory response in the muscle.  There is no distinct 
delineation between the degenerative processes (stages 1-3) and the regenerative stage 
(4), but there is clear evidence of myofiber regeneration by 4-6 days post-injury and by 
10-14 days most of the injured muscle fibers appear normal (4).  
To induce eccentric muscle injury in a laboratory setting, researchers have utilized 
various activities such as forearm extension, knee flexion, knee extension, eccentric 
stepping, or downhill running (23, 58-61).  However, due to their lower frequency of use, 
the forearm flexors and extensors are more susceptible to damage than the knee flexors 
and extensors (61).  Regardless of the muscle or muscle group that is injured, the damage 
manifests itself in the form of local pain/soreness, swelling, an increase in intramuscular 
proteins in the blood, inflammation, and a temporary decrement in function of the injured 
muscle (i.e., decreased force or torque production) (3, 14).  These symptoms will be 
discussed below. 
Skeletal Muscle Recovery from Eccentric Injury 
Skeletal muscle repair is a synchronized process involving the activation of 
various cellular responses. Following the initial (1) stage of muscle injury (actual 
injurious event), the autogenic (2) phase of muscle injury is marked by indigenous 
cellular systems that begin to degrade damaged tissue.  This stage is followed by the 
phagocytic stage (3) identified by the “typical” inflammatory response of neutrophils and 
   
 
11 
macrophages.  This stage precedes and overlaps with the regenerative (4) stage where 
muscle repair, regeneration, and growth are evident (4).   
Initial Stage of Muscle Injury 
The initial stage of muscle injury involves the traumatic mechanical event that 
triggers the various degenerative and regenerative phases involved in the injury process.  
The immediate events or symptoms associated with this stage are most likely the result of 
mechanical disruption in the sarcolemma, sarcoplasmic reticulum (SR), connective tissue, 
and contractile and E-C coupling proteins in the muscle fiber (4).  The high specific 
tensions associated with eccentric contractions result in mechanical disruption of these 
tissues.  This mechanical disruption may disrupt calcium (Ca2+) homoestasis and permit 
phospholipase A2 to come into contact with phospholipid substrates in the cell membrane 
resulting in lysis of structural components in the sarcolemma (62).  Phospholipase A2 
possesses a Ca2+ binding site and its activity increases as a function of Ca2+ concentration 
(63).  Increased activity of this enzyme can have several detrimental effects on the cell, 
including production of detergent fatty acids and lysophospholipids (64). 
Regardless of the mechanism and exact focal point, it is apparent that muscle 
fibers are acutely injured during eccentric exercise.  Histological data support this 
assertion.  Ogilvie et al., (1988) have identified three types of lesions muscles damaged 
by eccentric contractions:  (1) focal disruptions of the A-band, (2) Z-line dissolutions, 
and (3) clotted fibers (65).  In addition, data from other laboratories indicates damage to 
E-C coupling proteins immediately following eccentric contraction-induced muscle 
injury (66).  The combination of these factors and the processes involved in the 
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“secondary” injury phases results in an immediate and prolonged decrease in MVC 
torque, increased muscle soreness, muscle swelling, and intramuscular proteins in the 
bloodstream (10, 67). 
Autogenic and Phagocytic Stages of Muscle Injury 
The inflammatory process following the initial stage of muscle injury (autogenic 
and phagocytic stages) is predictable.  It has been suggested that the relationship between 
inflammation and muscle repair, regeneration, and growth is mechanistic in nature (24).  
Some of these processes disrupt muscle homeostasis and others promote muscle repair 
and regeneration (68).  Following modified muscle use and/or injury, neutrophils and 
macrophages rapidly invade the injured tissue.   
Neutrophils invade muscle tissue within one hour after eccentric muscle injury 
(69), and concentrations can remain elevated for up to five days (70).  Studies utilizing 
injury resulting from ischemia and reperfusion have yielded results suggesting that 
neutrophils are partly responsible for damage in healthy muscle (71).  This damage may 
be phagocytic in nature (21).  It may also result from the release of proteases that degrade 
cellular debris, and/or the release of cytolytic and cytotoxic molecules that can damage 
muscle (72).  Neutrophils may also cause further post-injury muscle damage via 
neutrophil-derived ROS (73). This is significant because it has been purported that ROS 
play a role in the initiation and progression of muscle fiber injury after the initial 
mechanical insult (74).  Regarding this theory, it is important to note that the extent to 
which neutrophils damage muscle is governed by the redox status of the muscle (75).  
Eccentric muscle contraction causes increased release of superoxide and hydroxyl 
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radicals that can react with other circulating compounds to form more cytotoxic agents 
(76).   
The exact role that neutrophils play in the regenerative process has not been 
determined.  However, recent research suggests that neutrophils may cooperate in the 
repair and remodeling process through oxidative or proteolytic modification of damaged 
tissue.  This modification serves to allow subsequent phagocytosis of debris by 
neutrophils or macrophages (67).  In support of this postulated role, studies examining 
myofiber regeneration in animals depleted of neutrophils show more tissue debris in 
muscles following recovery from injury; suggesting the possibility that the impaired 
capacity to oxidatively modify and remove tissue debris (via ROS-mediated damage and 
subsequent phagocytosis) could slow the regenerative process (77).  In addition, other 
animal experiments have shown that reduced neutrophil invasion into injured muscle or 
reduced neutrophil production of free radical oxidants results in reduced membrane lysis 
during inflammation (73).  Considering these data, it is possible that neutrophil-mediated 
damage to cellular structures is a necessary feature of muscle growth and repair. 
In injured muscle, the invasion of neutrophils is followed by the appearance of 
macrophages (78).  There is currently a limited understanding of the specific role that 
macrophages play in muscle following eccentric exercise-induced injury.  However, it 
has been demonstrated that macrophages play a major role in promoting muscle damage 
(in vitro and in vivo) and that their cytolytic capacity is increased by the presence of 
neutrophils (79).  The first macrophages to enter injured skeletal muscle fibers are of a 
phagocytic phenotype.  Their concentration is highest at damaged sites in injured muscle 
and their numbers decline at the end of the phagocytic stage of muscle injury (80).   
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Macrophages may also play a role in muscle repair and remodeling by increasing 
the rate of proliferation of myoblasts and/or by increasing the number of MyoD-
expressing cells (81).  Another possible connection between macrophage invasion and 
muscle repair and regeneration comes through studies investigating the effect of NSAID 
ingestion on the rate of muscle regeneration.  NSAIDs inhibit COX-2 formation; which 
has been shown (in vitro and in vivo) to reduce the rate of muscle repair following injury.  
This reduced rate of muscle repair coincides with a reduction in the number of 
macrophages in the injured muscle during regeneration (82-84). 
The first three stages of muscle injury have been discussed; the following portion 
of this review will focus on the regenerative (4) stage of muscle injury and its reliance on 
satellite cell activation, proliferation, and differentiation. 
Regenerative Stage of Muscle Injury 
The processes involved in the regenerative (4) stage of muscle repair, 
regeneration, and growth involve the activation, proliferation and eventual differentiation 
of myogenic cells known as satellite cells. These cells are the main source for myofiber 
repair in adults and are an extremely effective local cellular repair system (85).  They are 
also responsible for replenishment of the satellite cell pool following eccentric muscle 
injury (86).  Therefore, the activation, proliferation, and differentiation of satellite cells is 
an important part of this process. This sequence is controlled by a number of signals. 
It has long been apparent that healthy adult skeletal muscle has an extensive 
capacity to regenerate following exercise induced injury.  This capacity is mainly due to 
skeletal muscle satellite cells. These cells were first described by Alexander Mauro in 
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1961 (87).  Satellite cells are normally quiescent and are located in a space between the 
basal lamina and the sarcolemma of a muscle fiber (88).  Activation can be the result of 
signals originating from their associated muscle fiber or from the microenvironment.  
These signals include injury (89), degenerative disease (68), extrinsic mechanical stretch 
to the muscle fiber (86), secreted growth factors (90), or an increase in Nitric Oxide (NO) 
levels (91).  Regardless of the initiating signal, it is clear that activation is essential to 
initiating muscle growth and repair (88).  If activation does not occur, strength declines, 
muscles atrophy, and disability arises (92).   
Following activation, satellite cells can divide into self-renewing cells and/or 
committed skeletal myoblasts (93). To do this, satellite cells will leave their quiescent 
area and migrate outside of the basal lamina in order to proliferate, fuse, and differentiate 
to generate new muscle fibers or repair damaged ones (94)  Most committed cells 
(cycling myoblasts) become activated, leave the space between the basal lamina and the 
sarcolemma of the muscle fiber and proliferate (85).  Therefore, a majority of these 
myoblasts differentiate and contribute to new fiber formation.  However, some activated 
myoblasts can return to quiescence, thus replenishing the satellite cell pool (86). In a 
healthy, disease free individual, satellite cells are only activated following mechanical 
activity or muscle trauma (95). 
It is possible to inhibit or attenuate satellite cell activation, proliferation, or 
differentiation in healthy individuals following exercise-induced muscle injury.  Previous 
research suggests that treatment of muscle injury symptoms via NSAID ingestion results 
in attenuated satellite cell activation and protein synthesis (96, 97).  This attenuation of 
satellite cell activity has been attributed to inhibition of cycoloxygenase (COX) activity, 
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which governs prostaglandin synthesis.  In regards to NSAID treatment following muscle 
damage, it is clear that altering the inflammatory response via pharamacoligical 
intervention is contraindicated.   
The effect of NSAID treatment following exercise-induced muscle injury is well 
documented.  However, muscle regeneration also depends on other cellular processes 
(besides prostaglandin synthesis) involving non-muscle cells.  One of the earliest of these 
processes is the inflammatory response.  The inflammatory response facilitates 
myogenesis via phagocytosis of cellular debris and the release of chemoattractants and 
growth factors.  Many aspects of muscle regeneration remain unclear and most likely 
involve molecules that have yet to be defined. 
Antioxidants 
 Antioxidants can be classified as enzymatic and non-enzymatic. Enyzmatic 
antioxidants comprise the body’s natural defense system against oxidants (e.g., ROS). 
Non-enzymatic antioxidants are obtained from food or other dietary sources (e.g., 
antioxidant or multi-vitamin supplements).  Enzymatic antioxidants combat oxidants 
(e.g., ROS) in a very specific manner while non-enzymatic antioxidants are less specific 
(98).  Antioxidants function in complex synergy in order to protect cells against ROS-
induced damage.  Both types of antioxidants have intracellular and extracellular sites of 
action.  However, the sites of action for enzymatic antioxidants are primarily intracellular 
(99).  Typically, antioxidants protect against ROS by converting ROS into less reactive 
molecules (known as scavenging) or by preventing the transformation of less reactive 
ROS into more highly reactive forms (100).  This review will focus on antioxidants most 
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often used in research examining the effect of supplementation on symptoms of exercise-
induced muscle injury. 
Vitamin C 
 Vitamin C exists in two forms; (1) as L-ascorbic acid or in its oxidized form L-
dehydro-ascorbic acid (101).  Ascorbic acid is a water-soluble antioxidant vitamin that 
readily donates electrons to neutralize ROS (102).  It has two primary functions as an 
antioxidant; (1) to directly scavenge specific ROS and lipid hydro-peroxides and (2) 
helping recycle vitamin E from its radical form (100).  Vitamin C also recycles uric acid, 
glutathione, and β-carotene from their radical forms (103). 
 As a water-soluble vitamin, ascorbic acid is easily absorbed but it is not stored in 
the body (104).  It is transported in the plasma and located in the cytosolic compartment 
of neutrophils, monocytes, and lymphocytes.  Very small amounts have also been found 
in the cytosol of skeletal muscle fibers (101).  Vitamin C depletion-repletion studies have 
indicated that 100 mg/day of ascorbic acid results in saturation of neutrophils, monocytes, 
and lymphocytes.  Plasma concentrations of ascorbic acid continue to increase with doses 
up to 2500 mg/day.  However, plasma concentrations reach levels nearing saturation at a 
dose of 400 mg/day (105). 
Vitamin E 
 Vitamin E is a lipid-soluble antioxidant.  It is absorbed in the small intestine and 
exists in eight different natural forms.  The most biologically active form is α-tocopherol 
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(101).  This is the form of vitamin E that is most often used in studies examining the 
effect of supplementation on symptoms of eccentric contraction-induced muscle injury. 
 Vitamin E is transported in plasma lipoproteins and, as a fat-soluble vitamin, is 
able to be stored in the body (106).  Intense exercise has been shown to increase plasma 
α-tocopherol levels; suggesting that it is mobilized from other tissues in response to 
exercise (107). 
 Vitamin E functions as a chain-breaking antioxidant by stopping progression of 
the lipid peroxidation chain reaction.  It also acts as a scavenger of superoxide, hydroxyl 
and lipid peroxyl radicals (100).  This scavenging activity results in formation of a radical 
form of vitamin E that can be regenerated into a non-radical form by vitamin C (103). 
N-Acetylcysteine (NAC) 
 N-Acetylcysteine (NAC) is a contributor of antioxidant thiols (108). A thiol is an 
organo-sulfur compound that contains a carbon-bonded sulfhydryl group (109). N-
acetylcysteine is used in clinical practice to facilitate glutathione biosynthesis, thereby 
improving the enzymatic antioxidant defense system and possibly decreasing the 
damaging effects of ROS (108).  It acts as a scavenger of ROS including hypo-cholorous 
acid, hydroxyl radical, and hydrogen peroxide (110). Furthermore, NAC has been shown 
to decrease free radical production and oxidative stress at rest and during prolonged 
exercise (111).  Therefore, it is possible that NAC supplementation may reduce the 
oxidative stress and muscle soreness induced by eccentric exercise. 
 Previous studies examining the effect of NAC supplementation on symptoms of 
exercise-induced muscle injury have utilized a NAC dosages of 1,800 mg/day (112), and 
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10 mg/kg of bodyweight (113, 114).  The dosage of NAC utilized in clinical practice is 
commonly between 600-1500 mg/day (115-117). At dosages of 1,200 mg twice daily or 
lower, NAC is well tolerated.  However, doses higher that this are associated with a much 
higher rate of unpleasant side effects such as nausea, cramps, and diarrhea (118). 
Effect of Pharmacological Intervention on Muscle Injury 
The role of ROS in secondary damage following eccentric contraction-induced 
muscle injury points to a potential justification for pharmacological intervention via 
antioxidant supplementation or ingestion of NSAIDs.  However, treatmen  A reduction in 
ROS-induced muscle damage would possibly serve to reduce symptoms associated with 
eccentric contraction-induced muscle injury. 
Reduction in Free Radical Formation 
In an attempt to examine the effect that reduction of free radical formation has on 
the secondary injury process, Nguyen et al., (2003) found that a decrease in superoxide 
production was associated with a reduction in mouse muscle membrane damage; 
revealing a possibly causal relationship (119).  These findings seem to agree with those 
of Smith et al., (1989) who found that administration of the superoxide combatant 
superoxide dismutase (SOD) was associated with a decrease in muscle damage following 
exercise-induced muscle injury (120).  In an investigation examining the role of ROS in 
muscle damage and inflammation, Aoi et al., (2004), concluded that delayed-onset 
muscle damage induced by prolonged exercise is partly related to inflammation via 
phagocyte infiltration caused by ROS.  When these researchers administered doses of α-
tocopherol (an antioxidant), they found that this substance had the ability to attenuate 
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inflammatory changes normally associated with muscle injury (121).  Weinheimer et al., 
also demonstrated that inhibition or attenuation of the inflammatory response resulted 
from NSAID ingestion.  In this case (and as previously stated), it was concluded that the 
drugs inhibit the formation of prostaglandins; which are important mediators of the 
inflammatory response (122). These data suggest that alterations in the inflammatory 
response via antioxidant supplementation or treatment with NSAIDs may attenuate the 
inflammatory process following eccentric contraction-induced muscle injury.   
Non-Steroidal Anti-Inflammatory Drugs 
In many situations, attenuation of the inflammatory response would seem to be a 
positive outcome and studies such as this would seem to offer support for use of 
antioxidant supplements or NSAIDs during recovery periods.  Attenuation of this 
response could potentially reduce symptoms such as swelling, soreness, and stiffness.  A 
reduction in these symptoms could result in a faster return to training and/or competition.   
Promoting the acceleration and improvement in recovery has been the aim of 
many researchers, coaches, athletes, and casual exercisers.  In their own way, each of 
these groups has attempted to determine if the healing and recovery process can be 
altered (through pharmacological agents, supplementation, additional rest, and/or 
additional exercise) in order to improve performance by accelerating and/or aiding 
recovery from exercise induced muscle injury (57).  The previously mentioned studies 
demonstrate that NSAID treatment and/or antioxidant supplementation may reduce the 
inflammatory response following exercise induced muscle injury.  However, what impact 
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does this attenuation have on recovery of muscle function following exercise-induced 
muscle injury? 
 Studies examining treatment of the symptoms of exercise-induced muscle injury 
via ingestion of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) suggest that the 
inflammatory process (e.g., the initial stages of necrosis and phagocytosis of injured 
myofibers) plays an important role in the recovery process (121, 123-125).  As previously 
stated, the initial stages of the inflammatory process involve an increase in the production 
of ROS (121).  In order to determine the effect of a reduced inflammatory response on 
satellite cell activation, Mackey et al., (2007), and Weinheimer et al., (2007) examined 
the effect that NSAID ingestion has on satellite cell activation in trained athletes.  Both of 
these previously mentioned studies found that ingestion of anti-inflammatory agents was 
associated with a significant decrease in satellite cell activation and protein synthesis 
following endurance exercise or exercise-induced muscle injury (124, 125).  Therefore, 
these studies suggest that a reduction in the inflammatory response may inhibit/reduce 
satellite cell activation following muscle injury.   
Considering the previously mentioned research it is reasonable to conclude that 
attenuation of the inflammatory response would lead to an initial acceleration in the 
recovery process followed by a reduced rate and volume of muscle repair and 
regeneration in injured skeletal muscle (95).  The previously mentioned findings lead to 
the conclusion that ingestion of NSAIDs in an attempt to reduce inflammation following 
exercise induced muscle injury may lead to an attenuation in recovery of muscle function.  
 As previously stated, antioxidants have shown some promise as ergogenic aids 
because of their ability to neutralize muscle derived oxidants, such as ROS.  Reactive 
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oxygen species may play a causal role in muscle fatigue.  This role has been termed 
“redox braking” (126).  However, the observed inhibition of redox braking has possible 
negative side effects.  This “braking” has been proposed as a possible protective 
mechanism in exercising muscle.  Redox braking is thought to promote muscle fatigue in 
order to limit the amount of muscle damage due to continued use.  If this phenomenon is 
a protective mechanism in working muscle, then overriding this mechanism would most 
likely lead to increased muscle injury and increased recovery time (126).  In this case, the 
advantages of prolonged muscular activity and reduced fatigue would seem to be 
outweighed by the disadvantages of increased muscle injury. 
Antioxidants 
 Attempting to attenuate or inhibit the production of free radicals during recovery 
from exercise induced muscle injury may present a similar situation.  Conclusions on this 
topic are difficult as research dealing with the effect of antioxidant supplementation on 
muscle repair and regeneration following eccentric contraction-induced muscle injury is 
equivocal in nature and the factors involved in the muscular healing process and their 
connection to each other is still a new research area in laboratories around the world 
(123).  
As previously stated, the autogenic (2) and phagocytic (3) stages of eccentric 
muscular injury are associated with an inflammatory response in which phagocytosis and 
neutrophil respiratory burst result in the production of ROS (4).  Production of ROS 
imposes an oxidative stress upon the tissue (35).  Therefore, ROS have been implicated in 
the “secondary” damage that follows the initial mechanical insult.  The exact nature of 
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the relationship between ROS production, eccentric contraction-induced muscle injury, 
and muscle soreness is unclear (24).  However, recent data suggest that attenuation of 
neutrophil-mediated ROS production and secondary damage in injured muscle may have 
negative consequences (77). 
 Non-enzymatic antioxidants have been proposed to reduce ROS production and 
thereby reduce the secondary damage following eccentric contraction-induced muscle 
injury that is associated with ROS production (24).  Most of the research to date has 
focused on the effects of the antioxidant vitamins C (ascorbic acid) and E (tocopherol) 
(74).  Very few studies have investigated the effects of NAC on recovery of MVC torque, 
soreness, swelling, and inflammation following eccentric contraction-induced muscle 
injury. 
Animal Studies 
 There are many notable animal studies that have examined the effect of 
antioxidant supplementation on protection and recovery from exercise-induced muscle 
damage.  These studies usually involve supplementation for the period prior to an 
exercise bout with no post-exercise supplementation.  These studies usually involve 
vitamin E exclusively because many animals can (unlike humans) synthesize vitamin C 
(127).  Therefore, investigators do not normally provide vitamin C to animals. Vitamin E 
has been purported to reduce intramuscular protein diffusion by improving membrane 
integrity (74).    
 Many of these animal studies have utilized downhill walking, running or 
endurance exercise protocols to induce muscle injury.  Warren et al., (1992) investigated 
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the effect that five weeks of pre-injury vitamin E supplementation in rats had on indices 
of muscle damage following 150 minutes of downhill walking.  Injury in soleus muscle 
was determined by reductions in in-situ maximal tetanic force (∼20%), number of intact 
fibers per square millimeter and/or elevations in muscle glucose 6-phosphate 
dehydrogenase activity and plasma CK activity.  Measurements were taken either 
immediately or 2 days following the exercise intervention.  Although solues muscle 
vitamin E levels were significantly higher in the supplementation group, they showed no 
attenuation of muscle damage in any of the markers of muscle injury when compared to 
the control group (128).  These results suggest that pre-injury vitamin E supplementation 
does not exert a protective effect on muscle tissue and has little effect on the immediate 
and early (2d) symptoms of exercise-induced muscle injury.   This study did not include 
measurements at later time points, therefore it is not possible to form conclusions about 
the effect of vitamin E supplementation on the later stages of muscle recovery and 
regeneration. 
 Unfortunately, many of the exercise interventions utilizing downhill walking, 
running, or other forms of endurance exercise do not incur significant muscle injury in 
animals as a result of the prescribed exercise.  Instead, these studies focus on the 
contractile properties and/or the oxidative status of muscle immediately following 
fatiguing or endurance exercise.  Coombes et al., (2001) attempted to determine the 
effects of vitamin E and α-lipoic acid on muscle contractile properties.  Rats were 
supplemented with either vitamin E or α-lipoic acid for 8 weeks before measurement of 
maximum specific tension before and after an in-situ (tibialis anterior) fatigue (did not 
induce significant muscle injury) protocol.  No differences were found between the 
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groups in maximum specific tension before and after the fatigue protocol.  However, in 
two non-exercise control groups it was found that maximal twitch tension and tetanic 
force production at low stimulation frequencies (< 40 Hz) were significantly lower in 
antioxidant supplemented animals compared with control animals. In order to determine 
which antioxidant was associated with depressed force production, a second experiment 
was conducted using an in vitro rat diaphragm preparation. Results from these 
experiments indicated that vitamin E was associated with a decrease in skeletal muscle 
force production at low stimulation frequencies (129).  However, in a review of this 
study, McGinley et al., (2010) noted that the dose of vitamin E administered in this 
experiment was extremely (i.e., well above physiological levels) high which may have 
contributed to the depressed force production in treatment animals and the in vitro 
preparations. 
As previously mentioned, it has been proposed that oxidative stress may result in 
fatigue and further (secondary) muscle damage following exercise (111).  Therefore, 
other animal studies have utilized endurance exercise protocols in an attempt to 
determine the effect of antioxidant supplementation on indices of oxidative stress before 
and after exercise. In a study examining rat muscle before, during, and after 90 minutes 
downhill treadmill running (at a speed of 16 m/min at -16° grade) sixty-six male 
Sprague-Dawley rats were pretreated with a normal rat diet or diet + antioxidants (2,000 
mg vitamin C and 1,000 IU vitamin E/kg) for 2 weeks.  Rats were sacrificed either at rest, 
immediately, 2 hrs, or 48 hrs post-exercise.  Malondialdehyde (MDA) and protein 
carbonyl (PC) concentrations and glutathione status in blood, vastus lateralis, vastus 
intermedius, and soleus muscles were determined. You et al., (2005) found that a 
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combination of vitamin E and vitamin C supplementation resulted in reduced protein 
carbonyl (formed when amino acids are oxidized), (130) content in the vastus 
intermedius and soleus muscles of the treatment group.  This difference was significant at 
all time points.  However, this same effect was not present in the vastus lateralis muscle 
of the treatment group (131). These results suggest that a protective effect may be 
realized through antioxidant supplementation and that protective effect may be muscle-
specific.  These results would suggest a role for antioxidants to provide protection against 
the initial insult experienced during the bout of injurious exercise.  However, it is difficult 
to transfer conclusions from studies utilizing aerobic exercise to studies involving 
eccentric contraction-induced muscle injury. 
It has been established that chronic ingestion of NSAIDs results in reduced 
satellite cell activity and protein synthesis in aerobic athletes (97).   However, very few 
studies have examined the effect of antioxidant supplementation on muscle adaptation to 
aerobic exercise.  An interesting study by Strobel et al., (2010) addressed this question.  
This group examined the effect of vitamin E supplementation in male Wistar rats 
following a 14-week aerobic exercise program. The rats were divided into four groups: 
(1) sedentary control, (2) sedentary vitamin E, (3) exercise control, and (4) exercise 
vitamin E.  The animals ran on a treadmill 4 days/week at 70% VO2max for up to 90 
minutes/day.  The training program continued for 14 weeks.  Following training, there 
was a significant increase in markers of skeletal muscle mitochondrial biogenesis and 
antioxidant defenses.  However, antioxidant supplementation significantly reduced these 
markers (PGC-1α mRNA, PGC-1α and COX IV protein and citrate synthase) activity in 
both supplementation groups when compared to the non-supplementation groups (132).  
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These results indicate that vitamin E supplementation may suppress skeletal muscle 
mitochondrial biogenesis regardless of aerobic training status.  These results suggest that 
antioxidant supplementation may be contraindicated for endurance athletes.  The exercise 
involved in this study did not result in significant muscle injury so caution should be 
taken when transferring these results to populations experiencing significant (e.g., 
eccentric contraction-induced) muscle injury.  However, these results (i.e., reduced cyclo-
oxygenase activity) suggest that antioxidant supplementation may have a negative impact 
on the regenerative capacity of muscle following modified use. 
Other animal studies have utilized isolated eccentric contraction exercise 
interventions to induce muscle injury.  Van Der Meulen et al., (1997) investigated the 
effects that 5-8 days of vitamin E infusion had on markers of muscle injury following in-
situ performance of 225 eccentric contractions of the extensor digitorum longus muscle in 
rats.  The infusion significantly increased (3-fold) the muscle content of vitamin E.  
However, despite the increased muscle vitamin E content, the only significant difference 
between controls and rats in the treatment group was decreased serum CK response to 
injury.  There were no differences in other indices of muscle damage (133).  These results 
indicate that although vitamin E did not reduce initial muscle injury or attenuate 
secondary muscle injury, supplementation may prevent enzyme loss or membrane lysis 
following muscle damage.  Unfortunately, it was not possible to extend the data 
collection period of this study until baseline strength levels were recovered to determine 
if the differences at 3d had a significant impact on complete recovery of strength 
following eccentric contraction-induced injury.   
 Numerous human studies have attempted to investigate the effect of antioxidant 
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supplementation on symptoms of exercise-induced muscle injury.  This section divides 
those studies based on the antioxidant used in the supplementation protocol and the effect 
(if any) of antioxidant supplementation on symptoms of fatigue or muscle injury. 
Studies Utilizing Vitamin E 
 Many human studies have utilized downhill running to induce eccentric muscle 
injury.  Sacheck et al., (2003) examined the effect of 12 weeks 1000 IU/d vitamin E 
supplementation vs. a placebo on antioxidant status, creatine kinase, lipid peroxidation, 
and DNA damage at 6, 24, and 72 hours following 45 minutes of downhill running.  The 
males in the supplementation group displayed reduced serum CK values at 24 hours post-
exercise and decreased MDA levels immediately post-exercise when compared to the 
placebo condition (134).  However, one possible issue with this study is the possibility of 
a repeated bout effect.  Subjects performed a “baseline” version of the test at the pre-
supplementation session and performed another downhill running trial at 12 weeks post-
supplementation.  In addition, no measure of muscle function (i.e., MVC torque) was 
included in the post-injury assessment.  Therefore, the exercise intervention employed in 
this study may not have resulted in significant muscle injury as a result of the protective 
effect incurred following the baseline downhill running trial. 
This same issue (repeated bout effect) is seen in a two-part study examining the 
effect of 48 days vitamin E supplementation on eccentric muscle damage.  Cannon et al., 
(1990) and Cannon et al., (1991), utilized a double-blind, crossover design.  Subjects 
received either placebo or α-tocopherol until the day before a 45-minute downhill 
running protocol.  Supplementation was then resumed at 3 days post-exercise.  In each 
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portion of this study it was found that vitamin E had no effect on levels of circulating 
leukocytes, superoxide release from neutrophils, lipid peroxidation, or serum CK (135, 
136). Unfortunately, the authors did not include any measures of muscle function (e.g., 
MVC torque) before or after the exercise intervention.  In addition, the crossover design 
of this study did not or could not account for the existence of a repeated bout effect, 
making the second trial (regardless of supplementation condition) different from the first 
in regards to the muscle injury response to the bout of downhill running.  Therefore, it is 
not possible to form conclusions regarding the effect of vitamin E supplementation on 
exercise-induced muscle injury because the degree of injury imparted by the exercise 
intervention is unknown. 
The previously mentioned studies highlight a common problem when examining 
the research associated with antioxidant supplementation and exercise-induced muscle 
injury.  Many exercise interventions do not result in significant muscle injury (as defined 
by significant deficits in MVC torque) and many studies do not include any measures of 
muscle function (e.g., MVC torque) in their pre- and post-injury analyses.  This problem 
is illustrated in a study by McBride et al., (1998) who supplemented males with 1200 
IU/day of vitamin E for 2 weeks before they engaged in a heavy resistance exercise 
protocol.  This protocol involved previously trained individuals performing 4 sets and 10 
repetitions (16 sets total) of squat, bent over row, bench press, and military press (137).   
Following the exercise session, the experimental group displayed significantly lower 
plasma malondialdehyde (MDA) and CK values (138).  These results suggest that 
vitamin E supplementation may decrease muscle membrane disruption following 
exercise-induced muscle injury.  However, it is important to note that the researchers 
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primary intent was to examine free radical production following resistance training 
exercise and as a result, they did not include a measure of muscle function in their 
analysis.  In addition, subjects were experienced with strength training so the injury 
response may have been attenuated in this sample when compared to a sample of non-
exercising subjects.  Therefore, it is not possible to decipher the magnitude of injury 
experienced as a result of the exercise intervention. 
 Despite these shortcoming, Avery et al., (2003) conducted a study using the same 
exercise intervention to determine the effect of vitamin E supplementation on recovery 
from repeated bouts of exercise.  The only difference was that subjects performed 
repeated bouts of the exercise intervention.  Following 21 days of vitamin E 
supplementation (1200 IU/day) or placebo, subjects performed the first exercise bout.  
Subjects then performed the same exercise protocol twice more with two days separating 
each exercise session.  Reductions in strength and power were not significantly different 
between the two groups.  In addition, there were no significant differences in muscle 
soreness, MDA, or CK between the two groups.  These results indicated that vitamin E 
supplementation had no effect on recovery from repeated bouts of resistance exercise 
(139).  The reductions in MVC torque, although statistically significant, were not of the 
magnitude normally seen following heavy eccentric contraction-induced muscle injury.  
Reductions in maximal squat strength and maximal bench press strength were -11% and -
13% respectively.  Therefore, the magnitude of the injury experienced as a result of the 
exercise intervention may not have been significant enough to trigger the previously 
discussed response of muscle injury, inflammation, and regeneration. 
   
 
31 
Many studies have attempted to utilize exercise interventions involving eccentric 
injury of the quadriceps muscle group.  Due to frequency of use, this muscle group is 
difficult to injure and many exercise interventions have not resulted in significant 
decrements in MVC torque.   
However, Beaton et al., (2002) employed an exercise intervention that resulted in 
a significant initial deficit in isometric torque.  This group found that vitamin E 
supplementation (1200 UI/day for 30 days pre-exercise) had no effect on the symptoms 
of eccentric contraction-induced muscle injury of the knee extensors.  Following the 
exercise intervention, MVC torque was decreased by approximately 50% in both groups.  
Muscle biopsies taken 24 hours post-exercise revealed Z-band streaming but no damage 
to the structural proteins desmin and dystrophin.  Supplementation with vitamin E had no 
effect on MVC torque (at 2, 4, and 7 days post-injury), macrophage infiltration and serum 
CK levels following eccentric injury of the knee extensors (140).  However, the rapid 
return (isometric torque was not significantly different from pre-exercise levels at 4d 
post-exercise) to baseline levels of strength and the absence of edema in the subjects 
during the recovery period suggests that the injury response may not have been 
significant following the exercise intervention.  Considering the high number of 
contractions that were performed by the subjects, it is possible that fatigue may have been 
responsible for a portion of the immediate post-exercise strength deficits.   
The previously mentioned study also points to another potential problem with 
exercise interventions focusing on the quadriceps muscle group; it takes a large volume 
of work to injure this muscle group and the recovery is extremely rapid when compared 
to other muscle groups that are not used as frequently.  As an alternative, other 
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researchers have utilized forearm flexor exercise interventions to induce muscle injury.  
This muscle group is used less frequently than the quadriceps muscle group and is more 
easily injured.  The injury response following exercise is also much greater when 
compared to the quadriceps muscle group.  However, this muscle group is much smaller 
in size than the quadriceps so injury of this muscle group may not result in large-scale 
changes in blood-borne markers of inflammation when compared to exercise 
interventions such as downhill running.  In addition, muscle biopsies of the forearm 
flexors are difficult and risky to obtain when compared to biopsies of the vastus lateralis 
so researchers utilizing forearm flexor injury as their exercise intervention are normally 
forced to rely on blood-borne markers of inflammation to represent muscular events. 
Despite these previously mentioned limitations, injury of the forearm flexors has 
been utilized in one study examining the effect of vitamin E supplementation on recovery 
from eccentric contraction-induced muscle injury.  Phillips et al., (2003) used an exercise 
intervention involving eccentric contraction-induced muscle injury of the forearm flexors 
in 18-35 year-old males to examine the effect of vitamin E supplementation on symptoms 
of muscle injury.  They supplemented the experimental group with mixed tocopherols 
(vitamin E), flavonoids, and docosahexaenoate and the placebo group was given rice 
powder in capsules.  The supplements were taken 7 days before and for 7 days following 
an acute bout of eccentric exercise.  Following exercise, IL-6 levels were significantly 
lower in the experimental group three days following the exercise intervention (141).  
Unfortunately, the researchers did not include a measure of muscle function in their 
analysis and they did not follow the subjects for a period of time exceeding 3d post-
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exercise.  Therefore, it is difficult to determine the extent of muscle injury that was 
induced by the eccentric exercise. 
Studies Utilizing Vitamin C 
 Due to its water-soluble nature, vitamin C is not stored in the body in significant 
amounts.  The majority of vitamin C is transported in the plasma.  Therefore, it is 
plausible to predict that an acute dose of vitamin C (provided at the appropriate time) 
may impart protection against increased ROS production during injurious exercise by 
increasing plasma antioxidant levels.   
 Considering this, it is no surprise that a number of studies have utilized an acute 
dose of vitamin C immediately before or after a bout of injurious exercise. Thompson et 
al., (2001) administered an acute dose of vitamin C to subjects 2 hours before 90 minutes 
of intermittent shuttle running exercise.  Following exercise, the treatment group 
displayed significantly higher plasma and lymphocyte vitamin C levels.  However, there 
were no significant differences in serum CK, serum aspartate aminotransferase, or 
DOMS between the groups (142).  It is important to note that, considering the modest CK 
response and DOMS following exercise, this exercise protocol most likely did not result 
in significant muscle damage in either group.  Furthermore, the researchers did not 
include any other measures of muscle damage following the exercise.  As a result, it is 
difficult to make any conclusions based on this data. 
In another acute dose supplementation study Ashton et al., (1999) had subjects 
ingest 1000 mg of L-ascorbic acid 2 hours before performance of an incremental 
maximal exercise test on a cycle ergometer.  Pre- and post-exercise measurements of 
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electron spin resonance (ESR) signal of α-phenyl-tert-butylnitrone (PBN) adduct, lipid 
hydroperoxides, and malonlydialdehyde (MDA) were compared. Supplementation 
resulted in significant differences in these measures with individuals in the treatment 
group displaying lower post-exercise values in these free-radical related parameters, 
suggesting that vitamin C supplementation provided a protective effect against ROS 
production (143).  However, the methodology in this study suffers from a familiar flaw; 
researchers did not assess any indices of muscle damage following exercise. 
A few studies have utilized an exclusive post-injury dose of vitamin C instead of a 
pre-injury/exercise supplementation regimen.  Since vitamin C is primarily located in 
plasma and not stored in great quantities, raising plasma levels of vitamin C to 
correspond with increased ROS production may offer increased protection at a time of 
increased oxidant production.   
Another study by Thompson et al., (2003) found that 400 mg/day of vitamin C for 
3 days following 90 minutes of intermittent shuttle running (the same protocol as the 
previously mentioned study) had no effect on muscle soreness, plasma IL-6, serum CK, 
malondialdehyde (MDA) or MVC torque (144).  Due to the shared methodology (e.g., 
insufficient muscle injury protocol), this study shares the same limitations as the 
previously mentioned study by Thompson et al., (2001). 
 Due to their synergistic relationshiop, many studies have chosen to combine 
vitamin E and vitamin C supplementation.  However, in a unique study by Childs et al., 
(2001) researchers administered a combination of NAC (10mg/kg of body weight for 7 
days following exercise) and vitamin C (12 mg/kg for 7 days following exercise) to 
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subjects who had performed 30 eccentric contractions of the elbow flexors.  In this case, 
the supplementation regimen was associated with increases in serum CK and lactate 
dehydrogenase (LDH) indicating reduced cell membrane integrity (114).  However, 
MVC torque was not tested following injury so it is difficult to draw any definitive 
conclusions about the possible effect of the supplementation regimen on recovery of 
muscle function.  
The majority of vitamin C studies have used a pre-exercise supplementation 
strategy or the combination of a pre- and post-injury supplementation strategy.  A number 
of studies have demonstrated attenuated muscle damage and soreness when high does of 
vitamin C are administered prophylactically.   
In one of the first studies to examine the effect of vitamin C supplementation on 
symptoms of eccentric contraction-induced muscle injury, Kaminsky and Boal (1992) 
produced results demonstrating a reduction in DOMS following exercise-induced muscle 
injury.  They found that 3000 mg/day of vitamin C for 3 days prior to injury and 4 days 
post-injury decreased muscle soreness following 15 minutes of cyclic plantar flexion and 
extension (145).   
These results were encouraging and established a foundation for future research in 
this area.  In support of these findings, Bryer et al., (2006) also found that 
supplementation with 3000 mg of vitamin C each day for 14 days prior to 70 eccentric 
contractions of the forearm flexors and for 4 days post-injury resulted in a significant 
reduction in muscle soreness for the first 24 hours post-injury and at 96 hours post-injury.  
This study also found a significant attenuation in the glutathione ratio (which is used as a 
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marker of oxidative stress) for the first 24 hours post-injury.  However, despite the 
changes in soreness and markers of inflammation, the vitamin C supplementation had no 
effect on MVC torque (33).  This study points to a common theme in the research 
examining the effect of antioxidant supplementation on symptoms of muscle injury; in 
many cases inflammatory markers or markers of muscle damage are significantly lower 
in treatment groups but these reductions in inflammatory markers are not associated with 
significant differences in muscle function. For example, Thompson et al., (2001) gave 
subjects vitamin C or a placebo for 2 weeks prior to the aforementioned shuttle running 
test. Serum IL-6 increased immediately after exercise in both groups.  However, values in 
the treatment group were lower than in the placebo group 2 hours after exercise.  The 
treatment group also experienced a more rapid return to baseline IL-6 levels.  Although 
differences did not reach statistical significance, the treatment group also exhibited 
reductions in muscle soreness, MVC torque, and plasma concentrations of MDA.  These 
results suggest that prolonged vitamin C supplementation may have some modest 
beneficial effects on recovery from unaccustomed exercise (146).  These reductions 
(although non-significant) suggest that vitamin C supplementation may protect against 
secondary muscle damage following exercise-induced muscle injury.  However, Davison 
et al., (2006) used the same time period of supplementation with a higher dosage (1000 
mg/day) to investigate the effect of 2 weeks of supplementation with vitamin C on 
cortisol, adrenocorticotrophic hormone, interleukin-6, oxidative stress and neutrophil 
responses to 2.5 hours of cycling exercise at 60% VO2max.  In contrast to the previously 
mentioned study, the results yielded no significant differences between the experimental 
group and the placebo group (147). 
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Other results involving a pre-exercise supplementation regimen have suggested 
that vitamin C supplementation may improve the response of enzymatic antioxidants.  
Khassaf et al., (2003) attempted to determine the effects of vitamin C supplementation on 
the ability of lymphocytes to express protective enzymes and heat shock proteins (HSPs) 
following a bout of single leg cycling exercise.  Following the supplementation regimen 
and exercise bout, it was found that baseline activity of superoxide dismutase (SOD) and 
catalase were elevated in the treatment group when compared to the placebo group (148).  
These results suggest that vitamin C supplementation may result in up-regulation of 
protective enzymes with antioxidant properties.  This up-regulation may, in turn, provide 
protection against initial and secondary exercise-induced muscle damage. 
Tauler et al., (2003) reported similar results when they examined the effect of 
high amounts of vitamin C intake prior to a duathlon competition.  The researchers 
divided the subjects into two separate groups (n=16); a high dietary vitamin C intake 
group and a low dietary vitamin C intake group.  The high group was noted as having a 
vitamin C intake 7 times greater than the low group.  Blood samples were obtained at 
baseline, immediately post-race, and 1 hour post-race.  The low intake group displayed 
significantly higher plasma LDH level following the race (149).  These results suggest 
that the vitamin C supplementation may have resulted in a lower degree of cell lysis in 
the high intake group and that a higher vitamin C intake may have contributed to this 
lower degree of cell lysis. Therefore, vitamin C supplementation may offer protection 
against the symptoms of exercise-induced muscle damage.  However, it is important to 
note that the exercise interventions used in these studies were biased towards endurance 
activities and these results may not be transferable to studies involving higher intensity 
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activities leading to greater muscle damage (e.g., eccentric contraction-induced muscle 
injury). 
Although the results of these studies provide some evidence that pre- and post-
injury vitamin C supplementation may impart a protective effect during and after 
injurious activity there is also a great deal of evidence to suggest that vitamin C 
supplementation has no effect on the symptoms of exercise-induced muscle injury. 
In a recent study, Connolly et al., (2006) attempted to determine the effect of 
vitamin C supplementation on symptoms of eccentric contraction-induced muscle injury.  
Subjects ingested 3000 mg/day of vitamin C for 3 days prior to and 5 days following 
eccentric contraction-induced injury of the forearm flexors.  The supplementation had no 
effect on strength loss, point tenderness (DOMS), elbow flexor ROM, or subjective pain 
(150).  However, this study did not describe the training status of the participants and it 
included both males and females in the sample with unequal distribution between the 
groups.  As a result, there was a great deal of variability in the loss of strength following 
eccentric muscle injury.  Therefore, it is difficult to form conclusions regarding the effect 
of vitamin C on the symptoms of eccentric contraction-induced muscle injury based on 
these results. 
In another study examining the effects of a pre- and post-supplementation 
strategy, Thompson et al., (2004) used a 30 minute downhill (-18%) running protocol to 
induce eccentric muscle injury.  This same group had previously reported that vitamin C 
supplementation decreased the levels of plasma IL-6 following an unaccustomed bout of 
demanding exercise (shuttle running) (146).  Fourteen male subjects ingested 400 mg of 
vitamin C each day for 14 days prior to and 3 days following exercise.  Plasma vitamin C 
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concentrations increased in the supplementation group but there were no significant 
differences in circulating markers of muscle damage (CK, myoglobin, plasma IL-6), 
muscle function (MVC torque), or muscle soreness.  This study did not report the data 
associated with muscle function following injury.  However, the authors did state that 
near-complete recovery had occurred 48 hours following the exercise bout.  In addition, 
the average VO2max for subjects included in this study was 54 ml/kg/min for the 
supplementation group and 56 ml/kg/min for the control group.  These values do not 
place the subjects in an “elite” category of fitness, but the authors stated that subjects 
“regularly took part in a variety of activities but were unfamiliar with the exercise 
protocol used in the present investigation” (151).  This statement suggests that subjects 
were physically active and the mild injury response to the activity suggests that either the 
subjects were at least moderately trained or the protocol was not sufficient to induce 
significant muscle injury.  Therefore, it would be unwise to rely on the results of this 
study to make any conclusions regarding the effect of vitamin C supplementation on 
symptoms following exercise-induced muscle injury. 
 Other studies have suggested that pre- and post-injury vitamin C supplementation 
following eccentric contraction-induced muscle injury may be contraindicated.  Close et 
al., conducted a study during which subjects were given vitamin C (1000 mg/day) or a 
placebo 2 hours before and 14 days following downhill running exercise.  The 
supplementation group in this study displayed delays in recovery of MVC torque in spite 
of a smaller increase in MDA (152).  
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Studies Utilizing Vitamin E & Vitamin C 
 Vitamin C and vitamin E work synergistically.  Therefore, it seems reasonable to 
examine the effect of combined vitamin E and vitamin C supplementation on indices of 
damage following exercise-induced muscle injury. 
 As a result of this logic, numerous studies have examined the effect of 
simultaneous vitamin E and vitamin C supplementation on the symptoms of eccentric 
contraction-induced muscle injury.  Shafat et al., (2004) found that vitamin C (500 
mg/day) and vitamin E (1200 IU/day) taken for 37 days attenuated the decline in torque 
during 300 eccentric contractions of the knee extensors and attenuated the decline in 
muscle function for 2 days following the injury protocol when compared with a placebo 
group (153).  Similar results were seen from another study; this one involving eccentric 
contraction-induced muscle injury of the forearm flexors.  During the supplementation 
protocol, females were instructed to ingest a daily dose of vitamin C (1000 mg) and 
vitamin E (400 IU) for 14 days before and 2 days after injury.  The females in the 
treatment group displayed decreased blood protein carbonyls and MDA; results that were 
indicative of reduced oxidative stress and damage (74).  Considering the equivocal nature 
of the research involving exclusive vitamin C supplementation or exclusive vitamin E 
supplementation, these results provide evidence of a possible effect of antioxidant 
supplementation on symptoms of exercise-induced muscle injury.  However, there are 
contradictory findings from other studies examining the effect of simultaneous vitamin C 
and vitamin E supplementation on the symptoms of eccentric contraction-induced muscle 
injury. 
Mastaloudis et al., (2004a, 2004b, and 2006)) conducted a series of studies 
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examining the effects of concurrent vitamin C and vitamin E supplementation on 
symptoms of exercise-induced muscle injury following ultramarathon running.  
Numerous measurements were taken between three studies.  Subjects ingested vitamin C 
(1000 mg/day) and vitamin E (300 mg/day) for 6 weeks before participating in a 50-km 
ultramarathon.  The supplementation resulted in reduced lipid peroxidation and 
attenuated the exercise-induced increase in DNA damage in women, but not in men.  
However, antioxidant supplementation did not reduce inflammation and had no effect on 
muscle function (hamstring and quadriceps) or muscle protein levels in the blood 
following ultramarathon participation (154-156).  As with previous studies involving 
endurance exercise, caution should be taken when using these results to determine or 
predict the effect of antioxidant supplementation on symptoms of eccentric contraction-
induced muscle injury.   
In another study examining concurrent supplementation of vitamin C and vitamin 
E Petersen et al., (2001) utilized a downhill running protocol (90 minutes, -5% grade at 
75% VO2max) to examine the effect of combined vitamin C (500 mg/day) and vitamin E 
(400 mg/day) supplementation on protection from exercise-induced muscle injury and the 
post-injury response.  Researchers utilized a randomized, double-blind, placebo-
controlled design and had subjects ingest the supplements or a placebo for 14 days before 
and 7 days after exercise.  Plasma vitamin concentration showed a significant increase in 
the supplementation group.  However, following exercise, the groups exhibited identical 
exercise-induced changes in cytokine, muscle enzyme, and lymphocyte subpopulations 
(157).  However, this study suffered from methodological flaws similar to the previously 
mentioned study by Thompson et al., (2004) in that this study also included subjects that 
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were quite fit.  The average VO2max of the subject population was 63.8 ml/kg/min.  As a 
result, the active population included in this study would be difficult to injure.  In 
addition, there was no measurement of muscle function in this study so it is not possible 
to conclude that significant injury occurred as a result of the exercise protocol. 
As previously stated, it has been suggested that antioxidant supplementation may 
provide a protective effect during fatiguing or injurious exercise.  To investigate this 
possibility, Fisher et al., (2004) observed the effect of combined vitamin C and vitamin E 
supplementation on release of IL-6 from contracting human skeletal muscle.  Fourteen 
male subjects completed 3 hours of knee extensor (leg extension) exercise at a rate of 60 
extensions per minute.  Resistance was set at 50% of the highest intensity that subjects 
were able to maintain for 1 minute during a previous familiarization trial.  Net release of 
IL-6 during exercise was completely blunted in the treatment group when compared to 
the control group.  The post-exercise arterial IL-6 level was also significantly lower in the 
treatment group.  In addition, the control group displayed higher levels of Plasma 8-iso-
prostaglandin F (a marker of lipid peroxidation) when compared to the treatment group.  
The control group also realized increases in C-reactive protein and cortisol levels while 
the treatment group saw no changes in these levels (158).  These results suggest that 
simultaneous vitamin C and vitamin E supplementation may exert a protective effect on 
contracting skeletal muscle during exercise.  However, the low intensity of the exercise 
protocol utilized in this study makes it difficult to transfer these findings to individuals 
performing high-intensity, injurious exercise (e.g., eccentric muscle contractions). 
The body of research examining the effect of concurrent supplementation with 
vitamin C and vitamin E on symptoms of exercise-induced muscle injury or fatiguing 
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exercise is similar to the previously reviewed body of research examining exclusive 
vitamin E and vitamin C supplementation.  The available research involves distinct 
differences in exercise interventions, measures of muscle damage, and subject 
populations; making it difficult to form a uniform conclusion regarding the effect of 
antioxidant supplementation on symptoms of injurious or fatiguing exercise. 
 In addition, there are few studies that have directly compared the possible effects 
of vitamin C or vitamin E supplementation on symptoms of exercise-induced muscle 
injury.  Jakeman et al., (1993) compared the effect of 21 days of pre-injury and 7 days of 
post-injury vitamin C (400 mg/day) or vitamin E (400 mg/day) supplementation on 
muscle damage following 60 minutes of box-stepping exercise.  The only difference of 
significance associated with vitamin C supplementation was a significant reduction in the 
decline in Low Frequency Force (LFF) at the 20:50 Hz ratio following exercise.  No 
effects were found for vitamin E (159).  The same group conducted a similar study (again 
involving one hour of box-stepping exercise) using the same supplementation protocol.  
Prior to exercise eight subjects received 400 mg of vitamin C daily for three weeks before 
and one week after exercise, eight received 400 mg of vitamin E for the same period, and 
another group of eight subjects received a placebo.  Although plasma levels of each 
antioxidant rose in their respective groups, there were no significant differences between 
the groups in any blood borne measures of muscle damage or inflammation (160).   
 All of the previously mentioned studies supplemented subjects with 
pharmacological supplements (ascorbic acid, NAC, or vitamin E).  Connolly et al., 
(2006) chose to examine the effect of antioxidant-rich tart cherry juice on the symptoms 
of eccentric contraction-induced muscle injury.  Subjects received a daily dose of .682 L 
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of tart cherry juice or placebo of equal caloric content for 4 days prior to and 4 days 
following eccentric contraction-induced injury of the elbow flexors.  Subjects in the 
group receiving the tart cherry juice experienced a reduction in muscle soreness and an 
attenuation of the loss in MVC torque when compared to the placebo group (161).  The 
results of this study demonstrated a clear effect of antioxidant supplementation (smaller 
decrement in MVC torque) previous to and following eccentric muscle injury.  In fact, 
strength in the treatment group had recovered to above-baseline levels at 96h post-injury 
while strength in the placebo group had only recovered to approximately 85% of baseline 
strength.  Unfortunately, this study is the only work to examine the effect that 
consumption of an antioxidant rich food with anti-inflammatory properties on the 
symptoms of exercise-induced muscle injury when compared to an iso-caloric placebo.   
Studies Utilizing NAC 
 To date, numerous studies have examined the effect of NAC supplementation on 
symptoms of fatiguing contractions, skeletal muscle inflammation, and eccentric 
contraction-induced muscle injury.  The previously mentioned Childs et al., study and 
other works have led to differing conclusions regarding the effects of NAC 
supplementation on symptoms of exercise-induced muscle injury.  A majority of these 
studies have utilized animal models.  In addition, many of these studies have been 
ischemia reperfusion studies so care should be taken when translating the results of these 
studies to models utilizing eccentric contraction-induced muscle injury.  However, these 
studies do offer evidence suggesting that NAC supplementation imparts a protective 
effect on muscle tissue during and after injurious or fatiguing exercise. 
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 Kearns et al., (2010) investigated the effects of NAC in a model of compartment 
syndrome (essentially a ischemia and reperfusion model of injury).  Using rats, the 
authors investigated the effects of NAC supplementation on twitch and tetanic contractile 
function, tissue myeloperoxidase activity, and neutrophil respiratory burst activity at 1 
hour, 24 hours, and 7 days following decompression.  NAC supplementation had a very 
clear benefit for the rats.  Treatment preserved twitch and tetanic contractility, reduced 
neutrophil infiltration at 24 hours post-decompression, and reduced neutrophil respiratory 
burst activity.  Therefore, the authors concluded that NAC supplementation alleviated the 
symptoms of simulated compartment syndrome.  In these rats, treatment preserved 
muscle contractility, possibly by attenuating neutrophil activation and the resultant 
oxidant injury (162).  These results suggest that NAC supplementation exerts a protective 
effect on muscle tissue during the initial injury and possibly during the secondary injury 
process.  However, using these results, it is not possible to make conclusions regarding 
the longer-term effects of antioxidant supplementation on symptoms of muscle injury 
because no measurements were taken past 24 hours post-decompression.   
In a similar study, Bolcal et al., (2007) also used an ischemia reperfusion model to 
investigate the effects of NAC supplementation on the symptoms following muscle 
injury.  Forty-four New Zealand white rabbits were used in this study.  One group served 
as a control, another group served as an α-placebo (co-enzyme Q10) group, a third group 
served as a β-placebo group (β-glucan), and a fourth group served as the treatment group; 
receiving supplementation of NAC.  Following baseline measurements the common iliac 
artery was clamped and after 60 minutes of ischemia the limb was perfused for 180 
minutes.  Following perfusion, a biopsy was taken from the adductor magnus muscle and 
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blood samples were taken.  The control group displayed significant increases in 
malonyldialdehyde (MDA) while the NAC and placebo groups saw no significant 
increases in this variable.  The NAC supplemented group and placebo groups also saw 
increases in glutathione peroxidase and superoxide dismutase.  Levels of nitric oxide 
(NO) increased in all groups except the control group (163).  These results suggest that 
antioxidant supplementation (in various forms) may attenuate the initial injury response 
during and immediately after ischemia reperfusion.  However, no measurements were 
taken past the immediate post-perfusion time point; making it difficult to form 
conclusions from these studies regarding the effect of antioxidant supplementation on the 
secondary injury response following reperfusion injury. 
Koksal et al., (2003) also utilized ischemia reperfusion model to investigate the 
effects of NAC supplementation on symptoms of muscle in jury in rats.  Ischemia was 
induced via 4 hours vascular clamping of the hind limb and muscle injury was evaluated 
following 1 hour reperfusion in three groups; (1) a saline (control) group, (2) a DMSO 
group, and (3) a NAC group.  Plasma levels of CK, LDH, thiobarbituric acid reactive 
substances (TBARS), and blood HCO3, as well as muscle tissue TBARS, were measured 
at the end of reperfusion.  NAC and DMSO groups showed a significant attenuation of 
plasma CK, plasma TBARS, and muscle tissue TBARS when compared to the control 
group.  In addition, neutrophil infiltration in the DMSO and NAC groups was 
significantly lower than the control group (164).  These results agree with the previously 
mentioned studies; suggesting that NAC can improve the symptoms of ischemia 
reperfusion injury in an animal model. 
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As previously stated, one should take care when using the results of 
perfusion/reperfusion injury studies to make conclusions regarding the effects of NAC 
supplementation on symptoms of eccentric contraction-induced muscle injury.  However, 
results of other studies support the conclusions of the previously mentioned works. 
In another study utilizing New Zealand White Rabbits, Jiang et al., (2001) 
examined the role of NAC in preventing diaphragm injury produced by inspiratory 
reserve loading (IRL).  The rabbits were divided into three groups:  (1) control with no 
exercise, (2) exercise with no supplementation, and (3) exercise with supplementation.  
Free radical scavengers (superoxide dismutase, NAC, and mannitol) were given 
intravenously to the treatment group before and after the IRL intervention.  The rabbits 
were killed on day 3 to obtain the diaphragm muscles.  Hematoxylin and eosin staining 
indicated that abnormal muscle was more prominent in the exercise with no 
supplementation group when compared to the treatment group.  In addition, 
diaphragmatic contractility was found to be better maintained in the treatment group 
when compared to the exercise with no treatment group (165).  These results indicate that 
free radical scavengers may prevent the development of diaphragm injury during IRL. 
While these results offer evidence supporting the efficacy of NAC 
supplementation during periods of modified muscle use, it is important to note that these 
studies involved perfusion/reperfusion injury and diaphragm muscle injury.  The use of 
these exercise/injury interventions and/or muscle groups makes it difficult to transfer 
these results to different populations experiencing different sources of mechanical muscle 
injury.  
   
 
48 
However, work has been done examining the effect of NAC supplementation in 
exercising subjects or animals.  Pinheiro et al., (2010) used 24 male Wistar rats to 
investigate the effects of NAC supplementation on fatigue and muscle damage following 
60 minutes of electrically stimulated contractile activity.  Rats were divided into placebo 
and NAC groups before receiving treatment and being exposed to the exercise 
intervention.  In addition, tetanic force and muscle fatigue were assessed during, 
immediately following and 1 hour after the 60 minutes of contractions.  Plasma CK, 
plasma LDH, muscle content of ROS, thiobarbituric acid-reactive substances (TBARS) 
and myeloperoxidase (MPO) activity were measured 1 hour following the exercise 
intervention.  NAC supplementation resulted in an attenuation of the loss of force 
following the fatiguing protocol.   The NAC group saw force decreases of 38.22 ± 7.4% 
of the pre-exercise force values while force values for the placebo group decreased by 
70.8 ± 4.5%.  In addition, NAC treatment decreased plasma CK, plasma LDH, ROS, 
TBARS and MPO when compared to the placebo group (166).  These results suggest that 
NAC supplementation may result in attenuation of force loss during fatiguing exercise 
and muscle damage following this type of exercise intervention. 
A limited number of human studies have also examined the effect of NAC 
supplementation on symptoms of eccentric contraction-induced muscle injury.  Silva et 
al., (2008) had 29 participants ingest NAC (10 mg/kg/day) or a placebo for 14 days 
before and 7 days following eccentric contraction-induced injury of the forearm flexor 
muscles.  The NAC group displayed a significantly higher concentration of IL-10 (an 
anti-inflammatory cytokine) at day 7 when compared to the placebo group.  The presence 
of IL-10 inhibits pro-inflammatory cytokine production by activated monocytes and 
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macrophages.  Based on these results, the authors concluded that NAC supplementation 
played an important role in improving the endogenous anti-inflammatory response 
following eccentric contraction-induced muscle injury (113).  However, it is important to 
note that there were no other differences in other indices of muscle damage between the 
two groups.  In addition, these authors did not include MVC torque (or any other measure 
of muscle function) as a measurement of muscle damage.  Therefore, there is little 
justification for this conclusion based on the information obtained in this study. 
Other groups have attempted to induce eccentric muscle injury of the knee 
extensors to study the effect of NAC supplementation on the resulting symptoms.  
Kersick et al., (2010) supplemented subjects with a placebo, epigallocatechin gallate 
(EGCG) (1800 mg/day), or a high dose of NAC (1800 mg/day) for 14 days prior to 
eccentric exercise of the knee extensors.  The authors measured muscle soreness, serum 
markers of muscle damage, peak isometric torque, serum markers of oxidative stress and 
serum markers of inflammation at baseline and 6, 24, 48, 72 hours post-injury.  Of these 
measures, only soreness at 24 hours post-injury was attenuated in the treatment groups 
(112).  However, the magnitude of injury induced by the protocol utilized in this study 
was not comparable to similar studies examining eccentric contraction-induced muscle 
injury.  The baseline values for peak isometric torque were not reported, but peak 
isometric torque was not significantly different from baseline at 72 hours following the 
eccentric injury protocol.  Therefore, when compared to previous works examining 
recovery from eccentric muscle injury, the stimulus in this study was not sufficient to 
induce injury of a magnitude required for a valid examination of recovery.  
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Conclusion 
 The literature examining the effect of antioxidant supplementation on the 
symptoms of eccentric contraction-induced muscle injury is equivocal.  Many studies 
have identified a protective role for vitamin E, vitamin C, or NAC (alone or in 
combination) against fatigue, oxidative stress, muscle damage and/or inflammation.  
However, each study providing evidence for a positive effect is countered by another 
study providing equally convincing evidence for either no effect or, occasionally, a 
negative effect of antioxidant supplementation.  Definitive conclusions are complicated 
by numerous factors.  Studies vary greatly in the timing and dosage of antioxidants, 
subject population, and exercise intervention.  In addition, there is a great deal of 
variation in the magnitude of muscle damage that has been induced by different exercise 
interventions.  The metabolic demands of exercise interventions have varied from low 
(e.g., single limb eccentric contractions) to high (e.g., exhausting endurance exercise).  It 
is clear that the intensity and duration of the exercise intervention has a significant effect 
on ROS production.  For example, aerobic exercise results in a larger oxygen turnover 
and increased mitochondrial ROS production but eccentric exercise results in greater 
mechanical damage and greater ROS-mediated secondary damage.   
 Previous research has determined that NAC supplementation aids or improves the 
body’s natural (enzymatic) antioxidant defense system.  In addition, research examining 
the effect of NAC on maintenance of muscle force during fatiguing exercise suggests that 
NAC plays a role in reducing ROS production in muscle tissue during exercise.  These 
results also suggest that NAC may reduce further (secondary) post-injury muscle damage 
by inhibition or attenuation of ROS production.   
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Many animal studies have also demonstrated reduced inflammation following 
exercise-induced muscle injury in NAC-supplemented animals and seem to offer support 
for a protective effect of NAC during and immediately following a bout of injurious or 
fatiguing exercise.  These studies have also demonstrated a preservation of twitch 
characteristics following a fatiguing exercise protocol.  However, few studies have 
examined the long-term effects of NAC supplementation on recovery of strength 
following eccentric contraction-induced muscle injury in humans.  The studies that have 
attempted to examine this have either not included a sufficient exercise intervention 
(resulting in minimal muscle damage and short recovery) or have not included a measure 
of muscle function (e.g., MVC torque) following eccentric contraction-induced muscle 
injury. 
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CHAPTER 2 
THE EFFECT OF N-ACETYLCYSTEINE SUPPLEMENTATION ON RECOVERY 
OF STRENGTH FOLLOWING ECCENTRIC MUSCLE INJURY 
Introduction 
Many individuals experience the symptoms of exercise-induced muscle injury 
following novel or unfamiliar physical activity (1).  The list of these symptoms includes 
delayed-onset muscle soreness (DOMS) and swelling (2), release of muscle proteins into 
the bloodstream (3), ultra-structural damage (4), and most notably, initial and continued 
decrements in muscle function (i.e., decreased ability to produce force) (5, 6).  Treatment 
of these symptoms through administration of antioxidant supplements or Non-Steroidal 
Anti-Inflammatory Drugs (NSAIDs) may attenuate muscle soreness and/or improve 
initial post-exercise recovery of strength (7-10).   
Antioxidant supplementation may reduce post-exercise (i.e., secondary) muscle 
damage through inhibition of Reactive Oxygen Species (ROS) production and a 
subsequent reduction in oxidative stress in human and animal tissues (11-14).  Results of 
studies examining the effect of antioxidant supplementation on muscle injury and 
regeneration are equivocal; some have found it to be contraindicated (15, 16), some have 
found no effect (17), and others have shown a beneficial effect (18, 19).   
Many studies have reported that antioxidant supplementation decreases the initial 
inflammatory response and/or is associated with attenuated strength deficits in the initial 
and/or short-term post-exercise time period (immediately post-exercise to three days 
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post-exercise).  N-acetylcysteine (NAC) supplementation has demonstrated a clear anti-
inflammatory effect in human and animal disease models (19-21).  However, few studies 
have examined the longer-term effect of supplementation (past three days post-exercise) 
on the recovery of muscular strength following exercise-induced muscle injury requiring 
recovery periods greater than three days (9, 10, 13, 22, 23).  It has been demonstrated that 
NAC supplementation attenuates inflammatory changes immediately following and up to 
three days after injurious exercise in animal models.  This attenuation is partly related to 
a reduction in neutrophil activation and/or phagocyte infiltration (9, 14).  
Reduction of the inflammatory response following muscle injury may be 
contraindicated as the ROS-mediated secondary muscle damage (in combination with 
neutrophil and phagocyte activation and infiltration) associated with the inflammatory 
response may be necessary for complete recovery of muscle function following exercise-
induced muscle injury (24-26).  Considering these findings, it seems possible that treating 
the initial symptoms of exercise-induced muscle injury may mean trading short-term 
gains for long-term negative consequences when individuals attempt to speed their 
recovery via pharmacological intervention.   
Supplements containing antioxidants are widely available and many individuals 
use them on a daily basis (27). Numerous animal studies indicate that the commercially 
available amino acid & antioxidant nutritional supplement N-acetyl cysteine (NAC) has 
an anti-inflammatory effect and/or increases glutathione levels which may impart a 
protective effect on muscle tissue during injurious exercise and decrease the loss of 
muscular strength and/or the magnitude of the inflammatory response (and other 
symptoms) immediately following exercise-induced muscle injury (9, 10, 19, 22, 23, 28).  
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However, there is research suggesting that NAC supplementation has no effect (28, 29) 
or that it may have a pro-oxidative effect following a bout of injurious exercise (15).  
Therefore, an initial positive benefit (e.g., smaller decrement in isometric torque 
production, reduced inflammation and secondary damage) may be followed by a negative 
long-term consequence; as seen with other treatments following exercise-induced muscle 
injury. 
The long-term effect of other treatments resulting in alteration of the 
inflammatory response can be seen in studies examining the effect of NSAIDs on 
recovery following exercise-induced muscle injury.  Over-the-counter doses of NSAIDs 
may result in supressed tissue protein synthesis following high-intensity eccentric 
exercise (30), or high volume endurance exercise (31), and there is evidence of inhibited 
recovery of muscular strength and hypertrophy following NSAID administration in 
animal injury models (32, 33).   
Considering the results of studies in this area and lack of data concerning the 
long-term effect of NAC supplementation on recovery of muscular strength following 
exercise-induced muscle injury, the effect of NAC supplementation on complete recovery 
of muscle function follwing exercise-induced muscle injury is not known.  Therefore, the 
purpose of this study was to determine the effect of pre- (7D) and post-exercise (10D) 
NAC supplementation on recovery of muscular strength following eccentric contraction 
induced muscle injury of the forearm flexors. 
Current research examining the effect of NAC supplementation before and 
following a bout of injurious exercise suggests that in the short-term, supplementation 
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may provide a benefit and reduce initial strength losses and inflammation following 
exercise-induced muscle injury (9, 10, 22, 23).  However, other studies have suggested 
that the initial protective effect (reduced inflammation and secondary damage and/or 
attenuated deficits in muscular strength) may result in long-term consequences (e.g., 
incomplete recovery of muscular strength) (15).  In addition, there is evidence suggesting 
that, in models of muscle injury, NAC supplementation may result in increased oxidative 
stress and enhancement of the post-exercise inflammatory response, resulting in inhibited 
or incomplete recovery of muscular strength following a bout of injurious exercise (30, 
34, 35).   
Specifically, it was hypothesized that NAC supplementation before (7D) and after 
(10D) a bout of eccentric exercise would result in a greater deficit in muscular strength at 
10D post-exercise in the NAC supplemented group when compared to the placebo group. 
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Methods 
Subjects 
Twenty-one non-smoking, “low risk”, females (as specified by guidelines of the 
American College of Sports Medicine) (36), from Georgia State University were 
recruited to participate in this study (See mean characteristics in Table 1, see individual 
descriptive characteristics in Appendix A).  Each subject was informed of the purpose 
and potential risks of participation before signing a written informed consent document 
approved by the Georgia State University Institutional Review Board (See Appendix B).  
During the screening process, each subject was asked to describe their current and past 
exercise habits to determine if they met the criteria for inclusion.  Subjects were excluded 
if they had participated in resistance training within the last six months, had recent biceps 
brachii or elbow injury, and/or had used anti-inflammatory medication or vitamin/mineral 
supplements within the six weeks prior to their participation.  Following an initial 
evaluation (see Appendix C), subjects meeting the criteria for inclusion in this study were 
then asked to avoid changing their current exercise habits (e.g., beginning a strength 
training program or a weight-loss exercise program) for the duration of the protocol.   
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Table 1. Subject descriptive characteristics (n = 21). 
To increase the probability of subject compliance with the protocol, each subject 
was urged to take the provided supplement on a daily basis and was reminded of this 
directive during each visit to the laboratory.  Subjects were asked to bring their pill boxes 
to each laboratory visit; allowing for a pill count to determine if the supplement was 
being taken as directed.  In addition, each subject was instructed to abstain from the 
consumption of alcohol and caffeine for 12 hours prior to all testing.  Subjects were also 
directed to refrain from treating symptoms of exercise-induced muscle injury imparted 
from the exercise protocol (e.g., non-steroidal anti-inflammatory drugs, massage, ice, 
etc.). 
Experimental Design 
This study was a 17-day, randomized, parallel design involving a dietary 
supplement versus a placebo.  Subjects reported to the Applied Physiology Laboratory at 
Georgia State University and were randomly assigned to a treatment (n = 11) or a placebo 
(n = 10) group for seven days before and ten days following an acute bout of eccentric 
exercise.  
Age Weight Height Age Weight Height
Subject (yrs) (kg) (m) Subject (yrs) (kg) (m)
Mean 20.50 68.91 1.70 Mean 21.00 67.27 1.68
SEM 0.97 11.87 0.06 SEM 1.00 9.19 0.09
Placebo (n = 10) NAC (n = 11)
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Subjects visited the laboratory a total of eight times during the 17-day duration of 
the study.  During their first visit and second visits, each subject received their NAC 
supplement (Sigma Aldrich©, 10 mg·kg-1 bw·d-1) or placebo (food-grade cellulose) and 
completed two maximal voluntary contraction (MVC) torque familiarization trials 
involving the forearm flexor muscles of the non-dominant arm. Each familiarization trial 
consisted of three attempts each at 90°,100°, and 110° of forearm flexion.   
Following the familiarization trials, subjects reported to the lab on day 7 of the 
study.  A baseline venous blood sample was taken from the dominant arm and additional 
blood samples were collected at 1D, 3D, 7D, and 10D post-exercise.  Each subject also 
completed a baseline subjective evaluation of muscle soreness using a visual analog scale 
(1-100).  Additional evaluations were made immediately post-exercise and at 1D, 3D, 
7D, and 10D post-exercise.  MVC torque, circumference of the upper arm and range of 
motion (ROM) of the elbow joint were also measured at these time points.  Following 
baseline measurements, each subject completed the exercise protocol designed to elicit 
eccentric muscle injury of the forearm flexors.  Measurements quantifying the symptoms 
of eccentric contraction-induced muscle injury were taken at the previously mentioned 
time points. 
Analysis of bloodborne inflammatory markers was done at different time points.  
These time-points were selected based on previous work demonstrating that serum CK 
peaks between two and four days post-exercise and returns to normal/baseline levels at 
ten days post-exercise (37-40).   In addition, Childs et al., (2001) found that serum IL-6 
levels peak at three days following a bout of eccentric forearm flexor exercise (15).  
Therefore, measurements of serum IL-6 were performed on pre-exercise and 3D serum 
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samples.  N-acetylcysteine supplementation has been purported to increase serum 
glutathione levels under normal (e.g., uninjured) conditions (41).  There is a large degree 
of inter-subject variability in regards to oxidative stress and reduced serum glutathione 
levels following eccentric exercise-induced muscle damage (6).  Therefore, pre-exercise 
serum glutathione levels were compared between the groups to determine if 
supplementation had an effect on serum glutathione under normal conditions. 
Supplementation 
During their first visit, subjects were given capsules containing either 10 mg·kg-1 
bw·d-1 of N-acetylcysteine (Sigma-Aldrich©) or a placebo (food-grade cellulose) divided 
into two doses per day.  Subjects were instructed to take the capsules two times per day 
(one with breakfast and one with their lunch) for the duration of the study (7D pre-
exercise and 10D post-exercise). 
Muscular Strength 
Muscular strength was represented by isometric maximal voluntary contraction 
(MVC) torque.  Due to the voluntary nature (subjects were asked to exert maximal effort 
but level of effort was still voluntary) of the muscular strength testing, MVC torque was 
defined as the peak isometric torque recorded during a four-second isometric contraction 
(procedure described below). 
Subjects performed all muscular strength (e.g., MVC torque) testing on a 
modified arm curl machine (see Figure 1) partnered with a load cell (Transducer 
Techniques® MLP 150, Transducer Techniques, Temecula, CA) and a signal conditioner 
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(Transducer Techniques® TMO-2, Transducer Techniques, Temecula CA).  One end of 
the load cell was attached to a bar on the arm curl machine and the opposite end was 
bound to the subjects arm with a wrist strap.  The signal conditioner was interfaced with a 
desktop computer running TestPoint® (Measurement Computing Corporation ©, Norton, 
MA) software.  
Clarkson et al., (1992) found that MVC torque is immediately reduced by 
approximately 50% immediately following performance of a bout of exercise similar to 
the bout employed in this study.  In addition, they found that MVC torque values 
gradually recovered and, for most subjects, was complete by ten days post-exercise.  
Therefore, MVC torque was measured on eight different occasions (two familiarization 
trials, pre-exercise, immediately post-exercise, and 1D, 3D, 7D, and 10D post-exercise).  
The first and second familiarization trials were conducted to acquaint the subject with the 
equipment and procedures in order to ensure that a valid maximal baseline peak MVC 
torque measurement was achieved. 
After a brief warm-up, subjects were asked to attempt three maximal voluntary 
contractions of the non-dominant arm forearm flexor muscles for a four second duration 
at 90°, 100°, and 110° of elbow flexion (measured with a goniometer) for a total of nine 
MVC torque attempts (three attempts x three different angles) during each data collection 
session.  Kasprisin et al., (2000), demonstrated that the isometric torque developed by the 
biceps brachii was significantly affected by joint angle during maximum voluntary 
contractions (42).  Therefore, measurements were taken at three different elbow joint 
angles.  To accomplish this, the seat and arm pad of the machine was adjusted to each 
subject’s height and each subject’s arm was securely placed in the testing equipment with 
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two straps; orienting the elbow in the same location before each trial and preventing any 
extraneous movement of the arm during data collection.  The subject’s elbow joint angle 
was then determined (via goniometer) and secured in that position.  To accomplish 
isolation of the biceps brachii muscle, each subject was required to elevate their feet off 
of the ground (resting on a step stool) during MVC torque trials.  In addition, a lab 
technician placed a hand on the subject’s back and shoulder of the non-dominant arm to 
ensure that the subject did not lean back during the testing procedure and that back and 
shoulder muscles were not involved during MVC torque trials. 
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Figure 1. Modified arm curl machine. 
Standard instructions to exert as much force as possible against the lever arm 
were given to each subject before an attempt.  For motivational purposes, verbal 
encouragement was provided during each four-second MVC torque trial.  Peak torque 
measured during the three attempts at each angle of elbow flexion was recorded for 
analysis.  A 60-second rest was given between each attempt.  The mean of all 9 attempts 
was used to represent mean peak torque at each time point. 
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Injury Protocol and Peak Eccentric Torque 
Subjects performed the eccentric exercise protocol on the same modified arm curl 
machine (see Figure 1) utilized during MVC torque testing sessions.  The eccentric 
exercise protocol consisted of 50 eccentric contractions (2 sets of 25 repetitions).  The 
eccentric contractions were performed using a resistance equal to 80% of the subject’s 
average peak MVC torque at 90°, 100°, and 110° of elbow flexion. 
Subjects were instructed to perform each contraction over a period of four 
seconds.  Peak eccentric torque was recorded during each eccentric contraction effort.  
Following each eccentric contraction, the resistance arm on the machine was raised back 
to the starting position by a lab technician; allowing the subject to avoid the concentric 
portion of the lift and rest between eccentric contractions. Subjects were given 30 
seconds of rest between repetitions and five minutes of rest between sets in order to 
prevent forearm flexor muscle fatigue.   Verbal encouragement was given during 
performance of the eccentric contractions. 
Range of Motion 
Range of motion (ROM) was measured at pre-exercise, immediately post-
exercise, and 1D, 3D, 7D, and 10D post-exercise.  Subjects stood with their non-
dominant arm in a completely relaxed position while looking away from the researcher 
performing the measurement.  This position was used to mark maximal elbow extension.  
Following achievement of this position, subjects were asked to flex their non-dominant 
arm until maximal voluntary flexion had been achieved. This position was used to mark 
maximal elbow flexion.  The difference between these two points was calculated to 
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represent total ROM.  The mean of three attempts was taken to determine mean ROM at 
each time point. 
Rating of Muscle Soreness 
Each subject rated the soreness of the non-dominant forearm flexor muscle group 
pre-exercise, immediately post-exercise, 1D, 3D, 7D, and 10D post-exercise.  Standard 
instructions to rate muscle soreness only (i.e., ignoring feelings of fatigue or weakness) in 
the elbow flexors were given to each subject prior to the subjective soreness rating at 
each time point.  Subjects rated their level of muscle soreness after doing an arm curl 
with a 2.5 lb. dumbbell.  Starting with their arm in a relaxed position at their side, each 
subject performed maximal flexion of their non-dominant (injured) arm a total of three 
times.  After each attempt, subjects indicated their subjective rating of muscle soreness 
by placing a pencil mark on a 100 mm visual analogue scale (See Appendix E) (43).  A 
score of “0” corresponded to a perception of “no soreness”, while a score of “100” 
indicated a feeling of “very, very sore.”  The mean of the three soreness ratings was 
calculated and used to represent subjective muscle soreness at each time point. 
Arm Circumference 
Non-dominant upper arm circumference was assessed pre-exercise, immediately 
post-exercise, and at 1D, 3D, 7D, 10D post-exercise. Upper arm circumference was 
measured at a point 2/3 of the distance between the acromion process and the lateral 
epicondyle of the humerus.  Three measurement marks were placed around the 
circumference of each subject’s arm with indelible ink before the first measurement and 
the same point was used for all successive measurements. Measurements were taken 
   
 
75 
using an original standard Gulick tape measure (Richardson Products, Inc. Frankfort, IL) 
while the subject allowed their arm to hang down by their side in a relaxed position. The 
mean value of three measurements at each time point was used for analysis.  
Blood Analysis 
Venous blood samples (approximately 3.0 mL) were collected during each visit 
into tubes containing a polymer gel and clot activator (Vacutainer, Beckton Dickinson, 
Franklin Lakes, NJ) for collection of serum. Serum was analyzed for Creatine Kinase 
(CK) activity at pre-exercise, 1D, 3D, 7D, and 10D post-exercise.  Blood samples were 
allowed to clot at room temperature for 30 min before being centrifuged between 2,000 
and 3,000 g for 15 minutes at 4 ± 2°C.  The separated serum was then transferred to a 
freezable tube and stored at -20°C until analyzed for serum CK activity, serum IL-6, and 
serum glutathione.   
Serum CK activity was measured in duplicate with a spectrophotometer 
(Beckman DU 650, Beckman Coulter, Inc. Fullerton, CA) using a CK reagent set (Pointe 
Scientific, Inc. Lincoln Park, MI) (See Appendix F).  Serum IL-6 levels were measured in 
duplicate with a microplate reader (Opsys MR, Dynex Technologies, Chantilly, VA) 
using human IL-6 ELISA kits (Ray Biotech, Norcross, GA) (see Appendix F).  Serum 
glutathione levels were measured in duplicate with a microplate reader (Opsys MR, 
Dynex Technologies, Chantilly, VA) using a QuantiChrom Glutathione Assay Kit 
(Gentaur Molecular Products, Kampenhout, Belgium) (See Appendix F). 
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Food Frequency Questionnaire 
Subjects completed a food frequency questionnaire at the conclusion of the study 
(See Appendix E).  This instrument was designed to determine subject’s consumption of 
antioxidant-rich foods for the duration of the study (7D pre-exercise and 10D post-
exercise).  There were five categories listed on the questionnaire with each category 
representing a group of high-antioxidant foods. Subjects were asked to record how many 
servings of each food they consumed during the seventeen-day period of the study.  Each 
category was weighted based on the antioxidant content of the food group.  Calculations 
for the categories were based on data obtained from Wu et al., (2004) (44). 
Statistical Analyses 
Data were analyzed using a group (NAC, Placebo) by time ANOVA with 
repeated measures on time-point measures of MVC torque, non-dominant forearm flexor 
muscle soreness, non-dominant upper arm circumference, serum CK, and serum IL-6 
activity.  Differences between MVC torque values at the three angles measured was 
determined through use of an arm angle (90°, 100°, 110° of elbow flexion) by time (pre-
exercise, immediately post-exercise, 1D, 3D, 7D, and 10D post-exercise) repeated 
measures ANOVA with repeated measures on time.  Percent decline in peak eccentric 
torque, pre-exercise glutathione levels, and results from the food frequency questionnaire 
were compared between groups using an independent samples t-test.  Statistical 
significance for all analyses was determined at an alpha level of p < 0.05.  Dependent 
samples t-tests were performed upon observation of a significant F-ratio in order to 
determine the location of any mean differences.  To reduce the risk of Type 1 errors, 
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Bonferroni adjustments were applied to all post-hoc means comparisons tests.  All 
statistical analyses were performed using SPSS 12.0 (SPPS, Chicago, IL) data analysis 
software. 
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Results 
Peak Eccentric Torque 
 Mean decline in peak eccentric torque during the eccentric exercise protocol was 
not significantly different between the placebo and NAC groups (39.3% vs. 38.1% 
respectively; p = .81).  Mean maximum peak eccentric torque, taken as the mean of the 
first ten repetitions performed, was significantly higher than mean minimum peak 
eccentric torque (represented by the mean of the last ten repetitions performed) in all 
subjects (46.9 Nm vs. 28.9 Nm; p < .01) (see data in appendix F).   
Muscular Strength 
There were no statistically significant differences in percent decline in force 
between the two groups at any time point following performance of the injury protocol (p 
= .386).  Additional analysis of percent decline in torque at each specific arm angle also 
demonstrated that there were no significant differences between groups at 90°, 100°, or 
110° of elbow flexion at any time point (p = .333, p = .287, and p = .494, respectively).   
Analysis of MVC torque absolute data (in Nm) revealed no statistically 
significant differences between the NAC and placebo groups at any time point (p = .240).  
There was a main effect for time (p < .01), and post-hoc analyses revealed that, following 
Bonferroni correction of the predetermined alpha level of .05, absolute MVC torque 
values were significantly different from pre-exercise immediately post-exercise, and at 
1D, 3D, and 7D post-exercise (p < .001).  Following Bonferroni corrections, it was 
observed that absolute MVC torque values at 10D post-exercise were not significantly 
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different than pre-exercise values (56.66 ± 13.50 vs. 52.72 ± 11.66; p = .007) (see Figure 
3). 
MVC torque values between angles were not significantly different at any time 
point (p = .971).  Thus, comparisons at each time point are based on a torque value 
calculated as a mean of all nine trials (three trials per angle) at the three different angles 
(90°, 100°, and 110° of elbow flexion) measured per time point.   
Subjects were familiarized with the MVC torque testing procedure after the 
second familiarization trial, as evidenced by the absence of significant differences 
between MVC torque measurements during the second familiarization trial and that 
measured immediately before the acute bout of eccentric exercise (p = 0.134) and an 
intra-class correlation coefficient of 0.99 (p < 0.01) between torque values at both time 
points (see all MVC torque data in Appendix G).   
In order to normalize values and account for subject size differences and 
differences in baseline MVC torque, results were expressed as percent decline in MVC 
torque from pre-exercise (i.e., baseline) values.  MVC torque declined significantly in 
both groups following the acute bout of eccentric exercise.  There was a main effect for 
time (p < .01), and values for percent decline in MVC torque (compared to pre-exercise 
values) were significant at all angles of elbow flexion immediately following (p < .001), 
and at 1D (p < .001), 3D (p = < .001), and 7D (p = < .001) following the bout of injurious 
exercise.  Post-hoc tests (using Bonferroni corrections) revealed that values for percent 
decline in MVC torque were not statistically different from pre-exercise at 10D post-
exercise (0% vs 6.43 ± 6.82%; p = .007) (see Figure 2). 
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Figure 2. MVC torque (Nm) at baseline (PRE), immediately post-exercise (POST), 1D, 
3D, 7D, and 10D post-exercise.   
 
* indicates values significantly different from pre-exercise (PRE) for placebo group.   
# indicates values significantly different from pre-exercise (PRE) for NAC group.   
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Figure 3. Percent decline in MVC torque measured at baseline (PRE), immediately post-
exercise (POST), 1D, 3D, 7D, and 10D post-exercise.  
 
* indicates values significantly different from pre-exercise (PRE) for placebo group.   
# indicates values significantly different from pre-exercise (PRE) for NAC group.   
Range of Motion   
There was a significant decrease in ROM for both groups following the bout of 
injurious exercise (see data in Appendix H).  There was a main effect for time (p < .01) 
and mean values for all subjects’ ROM were significantly different from baseline (pre-
exercise) immediately post-exercise (97.7°, p < .001) and at 1D (107.8°, p < .001), and 
3D (110.5°, p < .001) post-exercise.  Recovery to pre-exercise ROM values were 
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complete by 7D post-exercise for all subjects.  There were no significant differences in 
ROM of the injured arm between the placebo and NAC group at any time point (p = 
.539) following performance of the eccentric exercise protocol (see Figure 4). 
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Figure 4. Non-dominant elbow joint range of motion (degrees of flexion) at baseline, 
immediately, 1D, 3D, 7D, and 10D post-exercise. 
 
* indicates values significantly different from pre-exercise (Pre) for placebo group.   
# indicates values significantly different from pre-exercise (Pre) for NAC group.   
Rating of Muscle Soreness 
Each subject rated soreness of the injured (non-dominant) forearm flexor muscle 
group pre-exercise, immediately post-exercise, 1D, 3D, 7D, and 10D post-exercise using 
a visual analog scale (see data in Appendix I).  There was a main effect for time (p < .01) 
and mean soreness ratings for all subjects were significantly higher than pre-exercise 
ratings (.62 ± 1.05 mm) at 1D (29.41 ± 15.3 mm, p < .001), 3D (73.75 ± 8.7 mm, p < 
.001), and 7D (13.49 ± 8.91 mm, p < .001) post-exercise.  All subjects had returned to 
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baseline levels of muscle soreness at 10D post-exercise.  There were no statistically 
significant differences between the placebo and NAC group’s mean soreness ratings at 
any time point (p = .752) (see Figure 5). 
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Figure 5. Visual analog scale muscle soreness rating (mm) at baseline, immediately, 1D, 
3D, 7D, and 10D post-exercise. 
 
* indicates values significantly different from pre-exercise (Pre) for placebo group.   
# indicates values significantly different from pre-exercise (Pre) for NAC group.   
Arm Circumference 
Circumference of the injured arm was assessed pre-exercise, immediately post-
exercise, and at 1D, 3D, 7D, 10D post-exercise.  The mean value of three measurements 
at each time point was used for analysis.  Values for circumference were converted to 
change from baseline (pre-exercise) values in order to account for differences in subject’s 
arm circumference (see data in Appendix J).   
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There was a main effect for time (p < .001) following exercise-induced muscle 
injury and values were significantly higher than baseline (0mm) immediately post-
exercise (0mm vs. .11 ± .01mm; p < .001) and at 1D (0mm vs. .30 ± .21 mm; p < .001), 
3D (0mm vs. .52 ± .24 mm; p < .001), and 7D (0mm vs. .85 ± .25 mm; p < .001) post-
exercise.  Circumference values at 10D post-exercise were not statistically significant 
from pre-exercise values (0 mm vs. .13 ± .10 mm; p > .05).  There was no difference in 
circumference measurements (change from baseline) between the placebo and NAC 
group at any time point (p = .535) (see Figure 6). 
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Figure 6. Change in non-dominant arm circumference (mm) at baseline (PRE), 
immediately post-exercise (POST), 1D, 3D, 7D, and 10D post-exercise.   
 
* indicates values significantly different from pre-exercise (Pre) for placebo group.   
# indicates values significantly different from pre-exercise (Pre) for NAC group.   
Blood Analysis 
Serum CK levels peaked at 3D post-exercise (750 ± 468.92 U·L) for both groups 
and were significantly higher when compared to pre-exercise (154 U·L), 1D (225 U·L), 
7D (175.39 U·L), and 10D (50.12 U·L) post-exercise (p < .001) (see Figure 7).   
The coefficient of variation between duplicate samples at each time point was less 
than 5% (± 3.24%). There was not a significant group x time interaction (p = .449) (see 
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data in Appendix K).  Therefore, the treatment had no effect on CK response to exercise-
induced muscle injury.   
Analysis of IL-6 data indicated there was no significant difference between 
groups at either time point (p = .360) and there was no significant effect for time between 
pre-exercise and 3D serum IL-6 levels (22.09 ± 5.59 pg·mL vs. 22.21 ± 5.22 pg·mL; p = 
.973); indicating that the eccentric injury protocol had no effect on serum IL-6 levels 
following performance of the eccentric exercise protocol at this time point (see Figure 8). 
The coefficient of variation between glutathione samples was less than 5% (± 
3.5%).  There was no significant difference in pre-exercise serum glutathione levels 
between the placebo and NAC groups (3.18 ± .88 µM vs. 3.3 µM ± .61 respectively; p = 
.967) (see Figure 9) (see data in Appendix M). 
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Figure 7. Serum creatine kinase (U·L) at baseline (PRE), 1D, 3D, 7D, and 10D post-
exercise.   
 
* indicates values significantly different from pre-exercise (Pre) for placebo group.   
# indicates values significantly different from pre-exercise (Pre) for NAC group.   
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Figure 8. Serum glutathione (µM) at baseline.  There was no significant difference 
between groups (p = .967). 
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Figure 9. Serum IL-6 at baseline (PRE) and 3D post-exercise.  There were no significant 
differences between groups (p = .973). 
Food Frequency Questionnaire 
Scoring of the food frequency questionnaire revealed that there was not a 
statistically significant difference between the weighted scores (based on antioxidant 
content of the food group consumed) for the placebo (41.04 ± 8.04) or NAC (30.74 ± 
14.89) group in regards to consumption of high-antioxidant foods for the duration of the 
study (p = .057) (see data in Appendix N). 
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Figure 10. Food frequency questionnaire scores.  There was no significant difference 
between groups (p = .054). 
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Discussion 
The primary objective of this study was to determine the effect of the dietary 
supplement N-acetylcysteine (NAC) on recovery of muscular strength (MVC torque) 
following eccentric-contraction induced muscle injury.  Following performance of an 
injury-inducing eccentric exercise protocol, we found that there was no difference in the 
loss and subsequent recovery of muscular strength between the placebo and NAC 
supplement group at any time point (immediately post-exercise, 1D, 3D, 7D, or 10D 
post-exercise).  Therefore, the results of this study did not support our hypothesis.  In 
addition, NAC supplementation at this dosage had no effect on any of the other markers 
of muscle injury. 
 The response of skeletal muscle to an acute bout of eccentrically biased exercise 
has been well established.  The primary variable measured in this study was the decline 
and subsequent recovery of the ability to generate muscular force with the injured muscle 
group (represented as MVC torque).  Prior studies have found that force deficits are 
maximal immediately following a bout of eccentric exercise.  Depending on the injury 
model and the magnitude of injury, recovery begins within the first 24-48 hours and is 
usually (though not always) complete by three days to fourteen days post-exercise (45).  
Subjects in this study experienced a significant reduction in the ability to produce 
isometric force with the injured muscle group; MVC torque was reduced by 54.89% 
immediately post-exercise and most subjects exhibited a complete recovery of MVC 
torque (mean deficit of 2.78% at 10D post-exercise) in the subsequent ten-day post-
exercise period. 
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Previous works have also demonstrated that delayed-onset muscle soreness 
(DOMS) is noticeable twenty-four to forty-eight hours after the bout of injurious exercise 
and reaches a peak between two to four days following that exercise.  The localized 
muscle soreness and pain are gradually reduced following this peak and soreness is 
typically not evident by ten days post-exercise (46).  Subjects in this study also 
experienced the expected pattern of DOMS, rating a statistically significant increase in 
soreness (mean of 73.75 on a 100mm Visual Analog Scale) at 3D post-exercise and 
reporting little to no pain (mean 1.33 rating) at 10D post-exercise.   
Serum CK displays a delayed response to exercise-induced muscle injury; 
peaking two to five days following exercise before returning to baseline within 
approximately seven days (47).  Serum CK levels of subjects in this study demonstrated a 
statistically significant peak at 3D post-exercise (750.01 U·L), representing an 
approximate 5-fold increase from baseline, with a return to normal/baseline levels at 10D 
post-exercise (50.12 U·L).  The magnitude of this increase would have been greater with 
the exclusion of one subject who displayed an elevated pre-exercise serum CK level of 
1586.7 U·L.  The reason for this subject’s elevated pre-exercise CK is unknown.  
Exclusion of this subject would have reduced the mean pre-exercise (baseline) serum CK 
level to 78.69 U·L and reduced the mean 3D peak to 682.4 U·L; representing an 
approximate 8-fold increase in serum CK levels following the bout of eccentric exercise.   
Changes in bloodborne muscle protein levels (such as serum CK) are poorly 
correlated with decreases in MVC torque and there is a great deal of inter-subject 
variability in these measures when compared with MVC torque (37-40).  Therefore, 
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measurement of these proteins is not recommended as the sole representative measure of 
muscle injury. 
One study has documented an increase in IL-6 activity following eccentric-
contraction induced injury of the forearm flexors (48).  However, other studies have not 
reported a significant increase in IL-6 following similar forearm flexor eccentric exercise 
(2, 3).  Subjects in this study did not demonstrate an increase in serum IL-6 levels at 3D 
post-exercise.  Therefore, it seems likely that the relatively small muscle mass injured in 
this study was not sufficient to increase serum IL-6 levels found in serum following the 
bout of eccentric exercise or it is possible that serum IL-6 peaked at a different time point 
than those that were measured.   
Earlier works have also demonstrated that exercise-induced muscle injury of the 
forearm flexors is associated with a decrease in ROM of the injured arm (45).  Following 
a bout of eccentric exercise, range of motion is significantly reduced immediately after 
the exercise bout.  Total ROM remains significantly lower than pre-exercise levels until 
five to seven days post-exercise when values return to pre-exercise levels (5).  Results of 
this study clearly demonstrate that subjects’ injured arm ROM followed a predictable 
pattern after the bout of injurious exercise.  Mean ROM was significantly reduced 
immediately post-exercise (97.7°), at 1D (107.8°), and at 3D (110.5°) post-exercise.  
Values for ROM returned to baseline, pre-exercise values by 7D post-exercise. 
Eccentric exercise-induced muscle injury also results in swelling of the injured 
muscle.  Other groups have used arm circumference to represent muscle swelling 
following injurious exercise. These groups have reported that arm circumferences are 
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slightly elevated immediately post-exercise, peak between four and six days post-
exercise, and return to baseline levels by ten days post-exercise (45).  The changes in 
upper arm circumference of the injured arm also followed previously observed patterns.  
Subjects experienced a statistically significant increase in arm circumference of .30mm 
.53mm and .86mm at 1D, 3D and 7D post-exercise, respectively.   
 Considering these well-established findings, it is apparent that the bout of 
eccentrically biased exercise performed by subjects participating in this study resulted in 
a pattern of exercise-induced muscle injury and subsequent recovery that is consistent 
with previous findings.     
NAC supplementation is purported to increase enzymatic antioxidant levels.  In 
order to determine the effectiveness of the NAC supplementation on serum glutathione 
levels, pre-exercise serum glutathione levels were compared between groups.  Following 
the analysis, we found that the supplement dosage administered did not have a significant 
effect on serum glutathione levels when compared to a placebo group following a seven-
day supplementation period.  The dosage used in this study was consistent with that used 
in previous studies and was chosen to limit the possibility of side effects (GI distress, 
etc.).  Previous works had demonstrated a significant effect on glutathione levels (and 
other markers of inflammation or antioxidant content) using similar doses (49-51).   
Vats et al., (2002) demonstrated that a dose of 400 mg·d-1 of NAC was sufficient 
to offset changes in the glutathione ratio in response to high-altitude stress and Silva et 
al., (2008) observed an augmented anti-inflammatory response (increased IL-10 in the 
treatment group) associated with a dosage of 10 mg·kg-1 bw·d-1 of NAC (19, 49).  
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Kerksick et al., (2009) also demonstrated that subjects ingesting 10 mg·kg-1 bw·d-1 of 
NAC had significantly higher total blood antioxidant status following a seven-day 
loading period (28).  However, the possibility exists that the chosen dose was insufficient 
to have a significant effect on serum glutathione levels.  
Higher doses of NAC have been utilized in a number of studies; a dose of 7,200 
mg of NAC (four doses of 1,800 mg over thirty-six hours) was sufficient to increase 
whole-blood glutathione levels following treatment (52).  Similarly, a dose of 140 mg·kg-
1 bw·d-1 has also been associated with a significant increase in plasma glutathione levels 
(53).  However, these high doses were accompanied by a significant increase in side 
effects.  In addition, higher doses have also been associated with a cytotoxic effect; 
resulting in production of additional ROS (e.g., superoxide, hydrogen peroxide, and/or 
hydroxyl radical) (54, 55).  This supplement is supposed to have an antioxidant effect.  
However, under high doses and/or certain conditions (e.g., exercise-induced muscle 
injury) supplementation with NAC can have a pro-oxidant effect (15). 
It has been observed that normal levels of glutathione exert a feedback inhibition 
on the enzyme gamma-glutamyl-cysteine synthetase (56).  This may partly explain the 
non-significant increase in glutathione levels in healthy subjects with normal pre-
supplementation serum glutathione levels; normal pre-exercise levels in healthy 
individuals would most likely result in glutathione exerting a feedback inhibition on 
gamma-glutamyl-cysteine synthetase thereby by preventing or minimizing any changes 
following supplementation with NAC. 
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In addition to the possibility of a lower dose being insufficient, differences in 
serum reduced glutathione (or the ratio of reduced glutathione to oxidized glutathione) 
may have been found later in the study when oxidative stress was likely higher and 
subjects were experiencing the symptoms of exercise-induced muscle injury.  Therefore, 
future studies should include analysis of serum glutathione levels at different time points 
following injurious exercise. 
All subjects were repeatedly reminded and encouraged to take their supplements 
as prescribed.  Each subject was told to bring their pill boxes to each data collection 
session to allow for a pill count to determine if they were taking the supplement as 
directed.  In addition, subjects were questioned about their compliance with the 
supplementation regimen.  Using this method, the investigators have a high degree of 
confidence that subjects had taken the supplement as prescribed.  However, the 
possibility exists that subject adherence to the supplementation protocol was not 100%.  
Non-compliance by subjects in the NAC group may have significantly impacted their 
results (when compared to non-compliance by placebo group subjects) by reducing the 
frequency and dosage of NAC supplementation during the duration of the study.  
However, because of the blinded nature of the protocol, non-compliance could have 
affected each group equally. 
The arm curl machine that was designed for this project was based on a similar 
device used by Clarkson et al., (1992) to investigate the response to an acute bout of 
high-intensity eccentric exercise (45). The device used in this study was constructed by 
attaching hinges and a custom made arm to a pre-fabricated arm curl bench (Yukon 
Fitness, Cleveland, OH).  The custom made arm of the machine was designed to allow 
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attachment of a load cell (Transducer Techniques® MLP 150, Transducer Techniques, 
Temecula, CA).  The opposite end of the load cell was attached to a wrist strap. 
Following modification of the arm curl machine, the load cell was tested for 
calibration in tension.  This was accomplished by hanging weights from one end of the 
load cell while the other was attached to an overhead steel beam.  The results of this 
calibration procedure indicated that the coefficient of variation was less than 1% between 
three trials per load each day and less than 5% between days during a seven-day period 
(See data in Appendix N).  The load cell was also calibrated in concert with the arm of 
the custom-built arm-curl machine.  The coefficient of variation between trials (3 trials 
per day) and days for this form of calibration was also less than 5% (See data in 
Appendix O). 
The exercise protocol employed in this study is similar to that used in a 
substantial body of published research (2, 3, 5, 45, 47, 57-60).  It was not unexpected 
therefore, that all subjects experienced significant symptoms of exercise-induced muscle 
injury following performance of this exercise intervention (i.e., decline in isometric force 
production, muscle soreness, increased serum CK, decreased ROM, and increased 
circumference of the injured arm).   
Animal studies utilizing infusion of NAC have demonstrated that supplementation 
provides protection from the initial deficits in muscular strength associated with exercise-
induced muscle injury (9, 22, 23).  However, these findings have not been confirmed in 
previous human studies investigating the effect of NAC supplementation on the 
symptoms of exercise-induced muscle injury (15, 19, 28) and were not confirmed in this 
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study.  It has been well documented that NAC supplementation or infusion results in 
delayed fatigue during exhaustive exercise (61-63).  Therefore, it is possible that 
eccentric contraction induced muscle injury in humans, similar to that induced by the 
exercise protocol in this study, is a unique situation that is unaffected by NAC 
supplementation at this dosage and/or increased glutathione levels. 
In conclusion, a novel bout of eccentrically biased forearm flexor exercise 
resulted in muscle injury and a significant decrease in the ability to produce force for ten 
days. N-acetylcysteine supplementation had no effect on recovery of strength at any time 
point following the bout of injurious exercise.  These results suggest that NAC 
supplementation may not provide a benefit to athletes and casual exercisers attempting to 
treat the symptoms of exercise-induced muscle injury.  However, these results also 
indicate that supplementation with NAC in this dosage is not harmful under the specific 
conditions encountered in this study. 
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APPENDIXES 
 
APPENDIX A 
 
PHYSICAL CHARACTERISTICS OF SUBJECTS 
 
 
Age Weight Height Age Weight Height
Subject (yrs) (kg) (m) Subject (yrs) (kg) (m)
1 22 70.45 1.69 11 22 79.55 1.78
2 21 53.18 1.71 12 21 59.09 1.73
3 19 57.27 1.64 13 20 56.82 1.69
4 19 78.64 1.73 14 20 61.36 1.68
5 20 71.36 1.71 15 20 59.09 1.54
6 21 74.09 1.83 16 21 77.73 1.57
7 21 94.09 1.74 17 21 68.18 1.60
8 21 67.27 1.64 18 21 57.73 1.63
9 21 60.00 1.61 19 23 81.36 1.79
10 20 62.73 1.71 20 22 71.36 1.75
21 20 67.73 1.74
Mean 20.50 68.91 1.70
SEM 0.97 11.87 0.06 Mean 21.00 67.27 1.68
SEM 1.00 9.19 0.09
Placebo NAC
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APPENDIX B 
 
INFORMED CONSENT FORM 
 
 
  
110 
 111 
APPENDIX C 
 
HEALTH HISTORY FORM 
 
Applied Physiology Laboratory 
Department of Kinesiology and Health 
Georgia State University 
 
Health History 
 
All information given is personal and confidential.  The information will enable us to better understand you 
and your health and fitness habits. 
 
Subject Number_____________________  Date_________________________________ 
(granted by researcher) 
Address___________________________  Home Phone___________________________ 
 
City/State______________________  Zip Code______________________________ 
 
E-mail______________________________  Bus Phone_____________________________ 
 
DOB______________Gender______Height______Weight_________Race__________ 
______________________________________________________________________________________ 
Signs and Symptoms 
______________________________________________________________________________________ 
Have you ever experienced any of the following: 
(please circle yes or no) 
 
yes   no 1. Pain, discomfort, tightness or numbness in the chest, neck, jaw or arms. 
 
yes   no 2. Shortness of breath at rest or with mild exertion. 
 
yes   no 3. Dizziness or fainting. 
 
yes   no 4. Difficult, labored or painful breathing during the day or at night. 
 
yes   no 5. Ankle swelling. 
 
yes   no 6. Rapid pulse or heart rate. 
 
yes   no 7. Intermittent cramping. 
 
yes   no 8. Known heart murmur. 
 
yes   no 9. Unusual shortness of breath or fatigue with usual activities. 
 
If you answered yes to any of the above: 
 How often do you experience the symptom?______________________________ 
 
 Have you ever discussed the symptom with a doctor?______________________ 
 
 Explain the symptom in more detail:___________________________________ 
 
 __________________________________________________________________ 
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______________________________________________________________________________________ 
Major Risk Factors 
______________________________________________________________________________________ 
yes   no 1. Do you have a body mass index ≥ 30 or a waist girth >100 cm? 
 
yes   no  2. Have you had a fasting glucose of ≥ 110 mg/dl confirmed by measurements on at least 2 
separate occasions. 
 
yes   no  3. Has your father or brother experienced a heart attack before the age of 55?  Or has your mother 
or sister experienced a heart attack before the age of 65? 
 
yes   no 4. Do you currently smoke or quit within the past 6 months? 
 
yes   no 5. Has your doctor ever told you that you have high blood pressure? 
 
yes   no 6. Do you have high cholesterol? 
   Total cholesterol:_________HDL:______Date tested:_________ 
 
yes   no  7. Do you have a sedentary lifestyle? (sitting most of the day in your job with no regular physical 
activity) 
______________________________________________________________________________________ 
Medical Diagnoses 
______________________________________________________________________________________ 
Have you ever had any of the following?  Circle all that apply: 
 
Asthma    coronary artery disease  heart surgery 
(lung disease causing difficult breathing) 
 
Angioplasty   angina    hypertension 
(surgical opening of heart artery) (chest pain) 
 
Heart clicks   heart murmur   heart attack 
(abnormal heart sounds) 
 
Emphysema   bronchitis   stroke 
(lung disease)   (lung inflammation) 
 
Emboli    phlebitis    anemia 
(abnormal blood pressure)  (inflammation of vein) 
 
Cancer    emotional disorders   eating disorders 
 
Osteoporosis 
(decreased bone mass/density) 
 
Any special problems not listed above:___________________________________________________ 
 
If any of the above are circled, please give details and explain____________________________________ 
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______________________________________________________________________________________ 
General 
______________________________________________________________________________________ 
 
yes   no 1. Are you pregnant? 
 
yes   no 2. Do you have arthritis or any bone or joint problem?   
If yes, please explain:___________________________________ 
 
           
___________________________________________________________ 
 
yes   no 3. Do you currently exercise?   
     If yes, how long have you been exercising?___________________ 
 
       What do you do and how often?____________________________ 
 
yes   no 4. Are you taking any medication, vitamins or supplements? 
   Name them and their dosage (list both prescribed & over-the-counter 
medications) 
   Drug name & dosage  /  purpose of drug  /  prescribed or over-the-counter 
 
   ________________________________________________________________ 
 
   ________________________________________________________________ 
 
   ________________________________________________________________ 
 
______________________________________________________________________________________ 
 
My signature certifies that all of the above is true, to the best of my knowledge. 
 
 
Signature:_________________________________________  Date:_______________________ 
 
************************************************************************ 
STAFF USE ONLY 
************************************************************************ 
 
Comments:____________________________________________________________________ 
 
 
 
Stratification(circle one): Low Risk  Moderate Risk   High Risk         
 
Resting blood pressure:__________________Resting heart rate:__________________ 
 
yes   no Do meds affect BP or HR? 
 
Date:_______________________Initials:_______________ 
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APPENDIX D 
 
IRB PERMISSION LETTER 
 
INSTITUTIONAL REVIEW BOARD 
 
 Mail: P.O. Box 3999  In Person: Alumni Hall 
  Atlanta, Georgia  30302-3999  30 Courtland St, Suite 217 
 
 Phone: 404/413-3500 
 Fax:  404/413-3504 
October 6, 2010 
 
Principal Investigator: Doyle, James Andrew 
Student Principal Investigator:  Luke, Ryan 
Protocol Department: Kinesiology & Health 
Protocol Title: The effect of N-acetyl cysteine supplementation on recovery of strength 
after eccentric muscle damage. 
Funding Agency:  
Submission Type: Protocol H10478 
Review Type: Full Board Review 
Approval Date: May 20, 2010 
Expiration Date: May 19, 2011 
 
The Georgia State University Institutional Review Board (IRB) reviewed and approved 
the above referenced study and enclosed Informed Consent Document(s) in accordance 
with the Department of Health and Human Services.  The approval period is listed above. 
 
Federal regulations require researchers to follow specific procedures in a timely manner.  
For the protection of all concerned, the IRB calls your attention to the following 
obligations that you have as Principal Investigator of this study. 
 
1. When the study is completed, a Study Closure Report must be submitted 
to the IRB.   
 
2. For any research that is conducted beyond the one-year approval period, 
you must submit a Renewal Application 30 days prior to the approval period 
expiration.  As a courtesy, an email reminder is sent to the Principal 
Investigator approximately two months prior to the expiration of the study.  
However, failure to receive an email reminder does not negate your 
responsibility to submit a Renewal Application.  In addition, failure to return 
the Renewal Application by its due date must result in an automatic 
termination of this study.  Reinstatement can only be granted following 
resubmission of the study to the IRB. 
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3. Any adverse event or problem occurring as a result of participation in this 
study must be reported immediately to the IRB using the Adverse Event 
Form. 
 
4. Principal investigators are responsible for ensuring that informed consent 
is obtained and that no human subject will be involved in the research prior to 
obtaining informed consent.  Ensure that each person giving consent is 
provided with a copy of the Informed Consent Form (ICF).  The ICF used 
must be the one reviewed and approved by the IRB; the approval dates of the 
IRB review are stamped on each page of the ICF.  Copy and use the stamped 
ICF for the coming year.  Maintain a single copy of the approved ICF in your 
files for this study.  However, a waiver to obtain informed consent may be 
granted by the IRB as outlined in 45CFR46.116(d). 
 
All of the above referenced forms are available online at https://irbwise.gsu.edu.  Please 
do not hesitate to contact Susan Vogtner in the Office of Research Integrity (404-413-
3500) if you have any questions or concerns. 
 
 
 
Sincerely, 
 
 
 
Susan K. Laury, IRB Chair 
 
 
 
 
 
 
 
 
 
 
 
 
 
Federal Wide Assurance Number:  00000129 
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DATA COLLECTION FORMS 
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 APPENDIX F 
 
ASSAY INSTRUCTIONS AND PROCEDURES 
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GLUTATHIONE ASSAY KIT INSTRUCTIONS 
 
 





    
           
          
       


     


  
        
 
       
     

         
         




µ
        
       




        

      




µ
          



        






µµ
        µ   


 

µ
µ 
     


  µ    
µ

        

 
µµ
     µ   
µ
µµ



         

 
         

          

µ










β
        


 
µ  
  
  
µ
  
  
 
    
µ
     




 

 µ










          

 
      


        
      


 
      


 

µ
  
122 
INTERLEUKIN-6 ASSAY KIT INSTRUCTIONS 
 
 
 
                               RayBio  
Human IL-6 ELISA Kit 
 
 
 
 
User Manual 
(Revised Dec 16, 2009)   
 
                                     RayBio Human IL-6 ELISA 
Kit Protocol  
              
                               (Cat#: ELH-IL6-001) 
 
              
 RayBiotech, Inc. 
 
We Provide You With Excellent  
Protein Array System And Service  
 
 
 
Tel:(Toll Free)1-888-494-8555 or 770-729-2992; Fax:770-206-2393;  
 Web: www.raybiotech.com   Email: info@raybiotech.com  
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Reagent and Sample Preparation 
Bring all reagents and samples to room temperature 
Dilute Assay Diluent B 5-fold with distilled water 
 -5-fold = 4 parts distilled water and 1 part Assay Diluent B  
Spin vial of Item C (powder) 
Add 500 µl Assay Diluent A into item C vial & gently shake.  This prepares a 12,000 
pg/ml standard. 
Add 40 µl IL-6 standard (12,000 pg/ml) from vial C into a tube with 440 µl Assay 
Diluent A to make a 1,000 pg/ml solution 
Use the 1,000 pg/ml solution to make a dilution series (add each 200 ul to 400 ul Assay 
Diluent already in the tubes 
 
If the wash concentrate (20x) (Item B) contains visible crystals, warm to room 
temperature and mix gently until dissolved.  Dilute 20 ml of Wash Buffer Concentrate 
into 380 ml distilled water to yield 400 ml of 1x Wash Buffer 
Briefly spin detection antibody vial (Item F). 
Add 100 ul of 1x Assay Diluent B in to the vial to prepare a detection antibody 
concentrate.  Pipette up and down to mix gently.  The detection antibody concentrate 
should diluted 80-fold with 1x Assay Diluent B and used in step 4 of Part VI Assay 
Procedure. 
Briefly spin the HRP-Streptavidin concentrate vial (Item G) and pipette up and down to 
mix gently before use. 
Add 2 ul of HRP-Streptavidin concentrate into a tube with 198.0 ul 1x Assay Diluent B 
to prepare a 100-fold diluted HRP-Streptavidin solution.   Mix through and then pipette 
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50 ul of prepared 100-fold diluted solution into a tube with 15 ml 1x Assay Diluent B to 
prepare a final 30,000 fold diluted HRP-Streptavidin solution. 
Assay Procedure 
Bring all reagents & samples to room temp. 
Add 100 ul of each standard at sample into appropriate wells.  Cover and incubate for 2.5 
hours at room temperature with gentle shaking. 
Discard the solution & wash 4 times w/1x Wash Solution. 
 Wash by filling each well with Wash Buffer (300ul), using a multi-channel 
pipette.  Complete removal of liquid at each step is essential to good performance.  
After the last wash, remove any remaining Wash Buffer by aspirating or decanting.  
Invert the plate and blot it against clean paper towels. 
Add 100 ul of 1x prepared biotinylated antibody (Reagent Preparation step 6) to each 
well.  Incubate for 1 hour at room temperature with gentle shaking. 
Discard the solution and repeat wash step. 
Add 100 ul of prepared Streptavidin solution to each well.  Incubate for 45 min. at room 
temp with gentle shaking 
Discard the solution and repeat wash step. 
Add 100ul of TMB One-Step Substrate Reagent to each well.  Incubate for 30 minutes at 
room temperature in the dark with gentle shaking. 
Add 50ul of stop solution to each well.  Read at 450nm immediately. 
  
125 
CREATINE KINASE REAGENT KIT AND ASSAY INSTRUCTIONS 
 
 
  
 
  
Phone:  734-487-8300        Toll Free:  800-445-9853        Fax:  734-483-1592        www.pointescientific.com 
Creatine Kinase – MB 
(CK – MB) 
Reagent Set 
 
Intended Use 
The CK-MB Reagent is for the quantitative determination of the isoenzyme 
Creatine Kinase-MB (CK-MB) in serum. For in vitro diagnostic use only. 
 
Test Summary and Principle 
Creatine Kinase exists as dimeric molecules composed of M and B subunits 
that form the isoenzymes MM, MB, and BB.1 The subunits M and B are 
immunologically distinct. CK-MM and CK-MB are distributed primarily in the 
skeletel muscle and heart muscle, respectively, while CK-BB is present 
mainly in the brain and in tissues composed of smooth muscle.2  
Following acute myocardial infarction, CK-MB activity increases significantly 
and this elevation is highly specific for the laboratory diagnosis of  myocardial 
infarction.3,4 Although total CK activity usually increases following myocardial 
infarction, in some patients only the CK-MB activity increases, while the total 
CK remains in the normal range.5  In this procedure CK activity is measured 
in the presence of an antibody to CK-M monomer. This antibody completely 
inhibits the activity of CK-MM and half of the activity of CK-MB, while not 
affecting the B subunit activity of CK-MB and CK-BB. Due to negligible 
concentrations of CK-BB in the circulation, the remaining activity, multiplied 
by a factor of 2, represents the activity of the CK-MB isoenzyme. 
 
Reagents 
CK-MB Reagent (when reconstituted) 
ADP 2.0 mmol/L, G6PDH 2000 U/L, Creatine Phosphate 20 mmol/L, NAD 
2.0 mmol/L, Hexokinase (yeast) 3000 U/L, D-Glucose 20 mmol/L, Anti-
human CK-M Antibody (Mouse) - Sufficient amount to inhibit up to 2000 U/L 
of CK-MM at 37C. Also contains buffers, activators, surfactants and 
adenylate kinase inhibitors. 
 
Precautions 
1. For in vitro diagnostic use only. 
2. Normal precautions exercised in handling laboratory reagents should 
be followed.  Bo not pipette by mouth. Reagent contains sodium azide, 
which may be toxic if ingested.  Sodium azide may also react with lead 
and copper plumbing to form highly explosive metal azides.  Refer to 
Material Safety Data Sheet for any updated risk, hazard or safety 
information.  Dispose of used or expired reagents according to your 
laboratory and governmental requirements. 
 
Reagent Preparation  
Reconstitute reagent with distilled water as indicated on vial label. Swirl 
gently to dissolve completely. 
 
Reagent Storage and Stability 
1. CK-MB reagent is stable at refrigerated temperature (2-8C) until the 
expiration date on the label.  
2. After reconstitution, the reagent is stable 5 days when stored at 2-8C. 
 
Materials Required But Not Provided 
1. Spectrophotometer capable of absorbance readings at 340 nm. 
2. Accurate pipetting devices. 
3. Interval timer. 
4. Cuvets and/or Test Tubes. 
5. Mixer (Vortex type). 
6. Constant temperature bath, or heating block set at 37C or a 
temperature controlled cuvet well. 
 
Specimen Collection and Preparation 
All specimens used in this test should be considered potentially infectious. 
Universal precautions as they apply to your facility should be used for handling 
and disposal of materials during and after testing. Clear unhemolyzed serum is the 
recommended specimen sample. No special additives or preservatives are 
required. Serum CK appears stable for 3 days at 2-8C. It is recommended that 
specimens be assayed immediately after collection. Reconstituted control sera 
may show a decrease in CK activity in only a few hours. 
 
Interferences 
1. Extremely hemolyzed samples are not suitable for testing since they may 
contain high levels of adenylate kinase, ATP and glucose-6-phosphate which 
interfere with the assay to yield false results.  
2. Drugs and other substances which may interfere with the determination of 
CK activity have been listed by Young et al.6  
3. This procedure may overestimate CK-MB values if CK-BB activity in the 
serum is high. CK-BB activity is usually absent in sera from normal 
individuals and patients with myocardial infarction.7  
4. The presence of a macro form of CK-BB in the specimen should be 
suspected if the CK-MB activity measured by this procedure represents more 
than 20% of the total CK activity. 
 
Materials Provided 
CK-MB Reagent 
 
Procedure (Automated)  
Wavelength:    340 nm 
Reaction Type:    Kinetic 
Reaction Direction:    Increasing 
Reaction Temperature:   37C 
Sample/Reagent Ratio:   1:20 
Equilibration Time:    20 Seconds 
Read Time:    120 Seconds 
Lag Time:     300 Seconds 
Blank Absorbance Limit:   0.800A 
High Absorbance Change/Min:   0.375A/Min. 
Factor:     3376 
Low Normal:    0 IU/L 
High Normal:    24 IU/L 
Linearity:     175 IU/L 
 
The above parameters should be employed in programming automated analyzers 
for CK-MB. Consult your instrument manual for programming instructions. Specific 
programming applications for many automated analyzers are available from Pointe 
Scientific, Inc. Technical Service Department. 
 
Procedure (Manual) 
1.   Allow reagent and specimens to equilibrate to ambient room temperature          
prior to use. 
2.     Prepare CK-MB reagent according to instructions (see Reagent Preparation 
Section). 
3.     Zero spectrophotometer at 340 nm with distilled water. 
4.    For each sample and control, add 1.0 mL CK-MB reagent into a cuvet/test 
tube and warm for approximately 5 minutes at 37C. 
5.     Add 50L of serum to its respective tube, mix well and incubate for 5minutes 
at 37C. 
6.      After the 5 minutes has elapsed, read and record the absorbance. 
7.     Record the increase in absorbance at 60 second intervals for the next  
2 minutes (A/Min).  The rate of change should be constant. 
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APPENDIX G 
PEAK ECCENTRIC TORQUE DATA 
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PERCENT DECLINE IN PEAK ECCENTRIC TORQUE 
 
Subject % Decline Subject % Decline
1 41.87 11 43.18
2 30.41 12 37.77
3 39.40 13 44.05
4 39.97 14 30.31
5 47.52 15 34.55
6 35.18 16 53.61
7 29.30 17 34.89
8 46.68 18 46.43
9 30.73 19 28.57
10 52.35 20 41.08
21 29.23
Mean 39.34
SEM 7.95 Mean 38.05
SEM 8.21
Placebo NAC
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PLACEBO GROUP PEAK ECCENTRIC TORQUE DATA 
(Nm) 
 
 
1 2 3 4 5 6 7 8 9 10
1 49.41 51.11 44.97 47.56 39.38 57.33 69.00 36.48 35.93 65.18
2 49.22 56.44 44.64 46.87 39.47 61.06 64.89 36.69 36.68 67.75
3 49.49 57.87 42.49 48.77 40.13 62.43 64.21 38.72 37.78 63.96
4 49.96 56.87 41.72 47.39 38.78 66.68 63.36 38.25 38.43 62.26
5 48.36 53.75 40.86 48.92 40.62 61.90 64.82 37.87 35.81 60.39
6 48.00 53.47 41.11 48.73 37.35 25.41 63.54 37.83 34.15 57.47
7 48.15 48.70 40.18 49.52 38.87 66.58 59.05 39.53 36.49 54.81
8 46.96 51.65 37.61 46.98 36.13 65.76 53.68 33.24 34.07 54.88
9 45.81 46.21 42.60 49.78 34.85 66.90 54.58 33.77 34.05 55.81
10 43.81 49.90 37.08 51.36 34.16 64.92 57.00 32.43 36.49 51.71
11 48.26 48.87 36.99 47.69 36.24 62.37 49.83 32.66 32.98 46.68
12 44.09 50.20 34.80 42.71 33.90 60.62 73.07 33.83 28.50 46.43
13 43.14 47.32 33.36 39.38 32.07 65.62 61.23 28.51 32.49 48.29
14 42.41 47.18 34.77 42.19 30.81 51.00 57.59 32.80 33.37 46.63
15 43.91 47.81 33.96 43.67 31.34 56.40 56.17 33.93 32.62 46.55
16 41.93 48.50 30.07 41.49 31.01 50.97 58.38 34.31 32.92 46.37
17 41.14 45.45 33.05 45.59 31.67 54.22 60.89 30.54 31.96 43.24
18 40.47 47.38 31.28 38.86 30.34 54.52 57.50 28.40 30.48 44.46
19 41.70 45.43 34.47 42.63 28.41 52.48 57.30 32.86 26.30 46.00
20 41.16 46.21 32.84 43.58 27.31 53.20 54.16 32.73 27.29 37.56
21 41.82 44.67 32.82 37.33 27.00 56.87 59.89 25.70 25.63 40.67
22 39.95 44.29 31.40 39.22 27.94 56.02 52.34 30.80 25.30 41.45
23 38.77 43.14 29.54 44.99 27.41 51.20 52.34 28.56 27.11 41.06
24 38.14 42.63 25.80 37.84 28.41 48.67 53.52 34.34 29.17 42.07
25 38.35 43.08 29.90 45.67 26.52 47.17 50.59 25.99 30.63 39.02
26 37.52 41.22 34.60 38.53 20.92 49.17 45.86 24.51 30.96 41.96
27 38.95 41.22 33.01 38.36 31.45 48.31 55.60 27.29 34.57 44.59
28 36.95 43.18 32.77 40.40 27.17 48.84 48.11 27.94 31.68 39.13
29 37.41 37.31 32.05 37.94 27.54 45.92 50.11 28.14 28.56 39.68
30 37.30 33.94 29.25 32.98 33.70 46.84 47.47 24.90 28.71 38.19
31 34.40 37.79 32.46 39.55 30.04 41.26 54.90 20.71 32.62 37.01
32 25.03 36.32 33.62 37.03 41.13 38.60 45.52 28.71 24.50 43.87
33 35.48 38.14 33.27 37.54 26.09 47.37 51.04 31.81 26.60 32.36
34 34.13 37.20 30.04 39.95 23.55 41.75 51.87 28.80 28.83 35.23
35 33.66 50.77 28.67 38.21 24.88 41.79 45.51 31.93 28.22 32.60
36 33.82 38.49 27.64 36.59 23.46 42.35 46.51 24.13 29.50 27.36
37 31.42 42.34 34.04 35.20 28.48 45.07 42.97 21.19 24.87 27.94
38 32.49 37.26 26.46 37.21 23.66 41.80 49.36 27.84 24.59 28.88
39 32.35 36.66 29.65 32.33 22.60 35.27 45.02 31.54 24.54 34.67
40 27.81 37.83 28.83 49.02 26.97 42.10 43.63 21.52 27.08 31.02
41 30.37 37.16 25.11 35.17 19.31 40.46 38.50 22.69 26.10 34.43
42 28.92 34.58 26.66 41.20 19.74 37.99 45.78 20.40 26.05 25.92
43 29.74 39.59 23.83 34.63 17.37 39.34 42.36 21.80 28.22 32.83
44 27.51 41.44 22.18 30.33 20.92 38.89 44.07 17.95 26.08 32.82
45 26.86 35.62 24.28 32.78 21.12 27.48 46.10 18.22 24.74 27.03
46 25.37 33.82 30.18 26.89 22.20 38.00 38.38 19.86 24.43 25.84
47 28.25 35.07 24.77 24.74 25.98 33.76 38.51 17.48 21.83 20.40
48 27.92 38.37 28.66 25.03 18.46 33.36 45.65 20.78 23.27 29.13
49 26.24 33.89 21.62 16.56 15.57 32.81 46.68 17.63 25.51 26.41
50 27.34 36.48 23.13 24.32 18.61 30.97 48.18 17.71 23.03 28.34
37.83 43.48 32.30 39.62 28.82 48.60 52.53 28.52 29.63 41.37
7.5795 6.6382 5.8739 7.6132 6.8186 11.177 8.1014 6.4068 4.4193 11.556
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129 
NAC GROUP PEAK ECCENTRIC TORQUE DATA 
(Nm) 
11 12 13 14 15 16 17 18 19 20 21
1 64.11 44.99 38.31 45.54 36.62 36.50 40.01 38.79 70.09 55.71 46.53
2 62.42 45.20 35.66 44.73 34.54 37.32 38.60 38.83 66.11 57.11 47.77
3 64.83 45.72 36.21 44.61 37.10 40.10 37.95 37.71 66.58 57.99 48.01
4 63.98 41.75 37.15 45.13 35.87 39.59 37.89 44.95 66.95 57.68 42.96
5 63.57 42.09 35.76 44.40 34.18 37.26 36.76 38.73 61.73 56.64 48.43
6 60.07 41.29 35.30 44.09 36.60 36.42 33.19 41.05 63.81 57.99 45.51
7 59.05 42.80 33.16 43.31 36.21 36.12 34.87 31.63 50.52 53.31 43.11
8 59.47 42.76 33.27 42.06 37.98 35.14 36.08 37.81 62.44 56.92 44.44
9 57.63 40.02 32.16 42.83 36.84 34.95 33.21 24.03 62.31 78.17 40.71
10 57.40 38.02 28.79 43.35 31.77 36.70 35.95 24.39 60.44 54.30 41.46
11 57.12 39.82 28.18 43.98 37.86 34.80 35.58 24.39 62.20 50.89 43.77
12 55.67 39.03 27.72 43.68 35.86 32.92 34.25 23.64 60.62 52.68 45.41
13 53.63 36.60 33.73 44.48 36.54 30.72 33.01 37.76 57.31 56.31 42.69
14 54.48 36.65 28.44 41.96 35.77 32.98 32.46 38.73 57.13 53.88 43.34
15 53.30 37.44 26.60 40.82 36.12 31.92 32.47 33.85 57.43 52.29 75.87
16 51.93 36.06 27.41 43.00 34.53 31.01 31.23 43.80 56.23 49.97 42.29
17 51.66 34.92 28.68 45.86 36.38 29.67 30.54 30.23 54.54 51.57 42.18
18 48.53 34.38 27.67 43.12 35.09 29.00 30.73 36.65 58.47 44.74 41.46
19 45.83 35.71 27.52 42.16 36.07 29.53 30.47 29.83 55.45 45.22 42.45
20 46.88 35.08 21.43 40.99 34.80 28.59 29.35 20.29 57.60 48.31 41.41
21 45.96 34.33 28.85 42.31 35.13 26.59 30.03 28.98 51.86 47.99 40.55
22 43.93 35.62 25.40 43.03 34.86 26.87 29.78 25.60 53.92 46.91 40.50
23 42.82 34.87 26.13 43.01 36.58 26.27 29.21 30.44 56.98 47.02 41.68
24 41.27 33.51 23.61 43.63 34.15 25.36 28.60 20.97 50.85 46.37 41.11
25 40.24 30.06 25.83 41.75 34.44 24.31 28.71 25.09 50.12 46.51 38.53
26 46.91 34.56 22.93 38.43 30.33 25.70 29.55 33.40 51.49 44.12 38.53
27 46.19 36.85 13.58 38.79 34.14 23.97 31.70 31.73 55.46 44.52 38.16
28 46.16 35.74 17.86 38.34 36.22 24.34 30.33 36.87 54.98 41.52 38.16
29 46.58 33.28 18.59 37.75 34.15 25.29 30.02 34.31 51.17 44.21 36.66
30 44.37 36.15 12.53 39.07 33.26 22.88 29.60 32.47 51.49 40.66 38.33
31 43.31 31.12 16.96 37.94 35.87 22.48 27.29 22.40 56.28 40.28 36.09
32 43.47 31.86 16.91 38.94 34.86 21.70 27.52 23.87 54.37 35.24 36.75
33 43.70 30.36 17.21 38.79 34.23 20.90 27.42 23.73 46.79 39.64 38.40
34 42.23 31.73 11.76 36.64 33.93 20.49 28.89 23.09 46.38 38.47 37.49
35 40.33 33.28 15.55 39.28 32.69 21.37 27.11 27.02 47.76 37.41 36.89
36 42.31 28.13 8.79 39.99 30.88 21.50 24.79 24.50 43.53 38.17 34.17
37 40.55 32.18 18.72 38.38 30.24 22.70 26.52 23.52 47.36 32.23 32.93
38 39.73 31.50 20.62 37.59 27.68 20.38 23.86 23.87 42.87 36.00 39.29
39 38.40 28.78 19.83 35.34 27.69 18.97 27.41 22.27 49.26 37.44 38.18
40 36.64 25.11 19.51 35.76 26.90 19.15 25.47 18.00 44.64 34.92 38.33
41 38.90 28.71 21.78 34.08 26.52 19.87 22.82 20.39 47.68 36.11 36.82
42 36.39 26.49 23.40 32.24 26.09 20.29 22.95 21.54 49.22 35.05 35.41
43 35.87 30.36 18.50 32.71 23.67 16.75 22.46 15.27 49.21 34.59 33.40
44 36.29 27.45 17.46 33.40 24.27 17.50 25.84 17.28 46.25 36.84 30.62
45 33.96 28.62 18.82 31.56 22.51 17.23 24.67 26.47 45.20 36.63 31.35
46 34.21 24.42 19.40 30.91 22.07 16.37 24.88 20.21 42.44 31.50 31.06
47 33.00 24.27 19.42 30.06 22.52 15.44 24.48 16.02 39.63 31.96 30.57
48 34.21 24.74 18.00 28.27 21.86 17.00 23.65 18.83 47.66 32.73 29.26
49 33.71 25.00 18.36 27.13 22.52 15.73 21.70 18.32 40.20 33.47 28.99
50 31.48 24.18 18.32 26.29 22.11 15.48 23.86 17.42 43.20 36.30 30.23
46.69 34.07 23.95 39.23 32.18 26.28 29.71 28.02 53.32 45.13 39.76
9.595 5.889 7.383 5.169 5.101 7.323 4.695 7.963 7.502 9.698 7.254
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PERCENT DECLINE IN PEAK ECCENTRIC TORQUE STATISTICAL TABLE 
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APPENDIX H 
 
MEAN MVC TORQUE DATA 
(Nm) 
Subject FAM1 FAM2 PRE POST 1D 3D 7D 10D
1 62.87 62.02 62.07 31.95 32.50 40.79 51.52 59.96
2 55.80 57.53 57.98 26.50 27.48 28.89 41.42 46.58
3 52.75 52.55 52.39 23.08 22.60 33.59 40.60 51.41
4 57.80 58.96 59.42 25.05 26.05 37.01 48.32 52.22
5 37.66 47.41 43.68 24.84 25.75 33.76 39.51 46.64
6 75.75 75.52 73.30 36.26 36.54 43.86 54.67 67.15
7 68.87 79.20 78.08 36.49 50.29 50.10 70.85 71.26
8 46.78 47.24 47.45 21.74 24.12 34.65 46.53 46.08
9 44.35 44.34 45.23 16.46 18.76 25.46 36.87 42.99
10 76.81 74.31 73.98 26.92 28.64 46.35 55.94 65.16
Mean 57.95 59.91 59.36 26.93 29.27 37.45 48.62 54.95
SEM 13.20 12.68 12.49 6.35 8.90 7.78 10.19 10.14
Subject FAM1 FAM2 PRE POST 1D 3D 7D 10D
11 76.94 78.21 79.37 41.97 41.90 52.37 77.10 77.47
12 50.42 50.10 49.77 16.87 22.26 30.10 37.05 44.27
13 42.87 42.65 43.81 20.78 21.29 25.91 31.80 42.22
14 49.30 51.66 51.93 33.16 31.45 39.09 48.87 53.34
15 40.09 43.77 43.93 22.59 30.35 35.60 42.83 43.88
16 41.16 42.52 42.98 13.53 18.24 23.50 34.63 37.25
17 45.15 47.00 47.59 21.80 29.15 37.12 46.18 49.33
18 41.00 38.21 37.84 12.99 17.20 21.79 33.57 33.21
19 76.69 79.69 80.51 41.32 41.52 50.28 59.41 67.09
20 60.34 63.95 64.13 30.58 36.43 47.99 59.57 58.36
21 54.97 54.76 54.33 20.89 31.79 39.69 48.97 51.16
Mean 52.63 53.87 54.20 25.13 29.24 36.68 47.27 50.69
SEM 13.51 14.25 14.49 10.22 8.68 10.63 13.81 13.04
Placebo
NAC
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MVC TORQUE AT 90º ELBOW FLEXION 
(Nm) 
 
 
Subject FAM1 FAM2 PRE POST 1D 3D 7D 10D
1 63.77 62.61 62.60 31.98 32.85 41.13 51.72 60.27
2 55.15 57.39 57.80 26.32 27.39 28.55 41.64 47.74
3 53.86 52.85 52.93 24.57 21.50 34.06 40.96 51.95
4 56.35 58.61 59.08 25.13 26.29 37.52 48.52 53.27
5 33.47 47.83 43.66 25.17 27.48 33.49 39.87 46.83
6 73.99 75.07 73.21 36.99 34.91 43.89 54.34 67.61
7 63.97 79.21 78.22 36.22 50.52 50.76 71.50 70.66
8 47.72 47.80 48.05 20.98 24.47 35.23 47.11 46.57
9 44.24 44.32 45.24 15.97 18.93 25.74 37.13 42.53
10 78.28 74.33 74.13 27.72 27.89 46.75 56.38 65.59
Mean 57.08 60.00 59.49 27.10 29.22 37.71 48.92 55.30
SEM 13.55 12.52 12.44 6.51 8.84 7.93 10.24 10.01
Subject FAM1 FAM2 PRE POST 1D 3D 7D 10D
11 82.46 77.95 78.26 41.79 42.68 52.38 77.34 77.20
12 53.76 48.94 48.98 16.71 22.47 26.27 36.34 42.17
13 40.77 43.82 44.02 20.58 21.35 25.89 31.43 42.12
14 52.87 52.25 52.13 32.98 32.33 39.88 48.44 53.70
15 40.48 43.19 43.45 23.21 31.05 35.25 42.05 44.54
16 42.47 43.53 44.03 12.81 18.27 21.62 35.69 37.87
17 43.59 47.54 48.29 22.44 27.51 36.27 44.74 49.70
18 41.67 38.47 37.92 12.64 18.14 21.67 34.46 34.13
19 77.25 80.16 80.49 40.69 40.79 50.35 59.92 68.34
20 57.89 63.94 64.51 31.00 37.11 48.55 60.00 57.62
21 57.93 54.94 54.47 20.57 34.17 40.63 49.84 52.03
Mean 53.74 54.07 54.23 25.04 29.62 36.25 47.30 50.86
SEM 14.60 14.14 14.25 10.23 8.75 11.30 13.92 13.02
Placebo
NAC
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MVC TORQUE AT 100º ELBOW FLEXION 
(Nm) 
 
 
Subject FAM1 FAM2 PRE POST 1D 3D 7D 10D
1 63.27 61.31 61.33 32.46 32.74 40.62 51.36 59.74
2 57.12 57.85 58.33 26.56 27.79 29.40 41.36 46.05
3 52.58 51.95 52.05 22.83 22.58 33.67 40.68 50.79
4 59.68 59.69 59.87 25.17 26.25 36.71 48.42 52.14
5 39.39 47.97 43.92 24.99 23.82 33.78 39.48 46.37
6 74.00 75.44 73.46 36.57 36.60 43.57 54.89 66.94
7 67.02 79.31 77.73 36.19 50.13 49.77 71.20 72.92
8 46.63 47.05 47.10 21.21 24.06 35.50 46.64 46.05
9 44.26 44.41 45.62 16.87 18.87 25.47 36.51 44.32
10 77.41 74.12 74.24 26.51 29.86 46.13 56.05 65.43
Mean 58.14 59.91 59.36 26.94 29.27 37.46 48.66 55.07
SEM 12.64 12.64 12.44 6.39 8.96 7.56 10.34 10.38
Subject FAM1 FAM2 PRE POST 1D 3D 7D 10D
11 74.23 78.39 80.06 42.80 40.60 52.44 77.31 77.23
12 50.55 50.77 50.26 17.23 22.68 34.41 36.98 45.50
13 44.29 42.64 42.76 19.49 20.78 26.10 31.22 42.17
14 50.13 51.38 52.26 33.94 32.07 38.20 49.06 52.82
15 39.58 44.37 44.55 22.26 30.40 35.92 43.44 43.67
16 41.03 42.13 42.46 12.27 18.28 25.02 35.21 37.84
17 45.97 46.60 47.09 20.98 29.62 37.79 46.99 49.29
18 41.05 38.29 38.14 12.55 16.07 21.29 34.18 33.08
19 76.30 79.89 80.84 41.66 44.27 51.03 59.34 66.47
20 62.43 63.96 64.03 29.56 36.38 47.47 60.03 58.41
21 53.73 54.67 54.39 21.81 31.30 39.49 47.92 50.41
Mean 52.66 53.92 54.26 24.96 29.31 37.20 47.43 50.63
SEM 12.99 14.31 14.71 10.66 9.10 10.34 13.82 12.82
Placebo
NAC
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MVC TORQUE AT 110º ELBOW FLEXION 
(Nm) 
 
 
Subject FAM1 FAM2 PRE POST 1D 3D 7D 10D
1 61.56 62.15 62.29 31.41 31.92 40.61 51.46 59.87
2 55.14 57.37 57.82 26.61 27.25 28.71 41.25 45.94
3 51.81 52.85 52.18 21.83 23.73 33.03 40.16 51.48
4 57.37 58.58 59.30 24.85 25.60 36.79 48.03 51.26
5 40.12 46.42 43.45 24.35 25.96 34.02 39.18 46.73
6 79.25 76.04 73.25 35.20 38.11 44.11 54.77 66.89
7 75.62 79.08 78.29 37.06 50.21 49.77 69.86 70.22
8 46.00 46.87 47.19 23.03 23.84 33.21 45.85 45.63
9 44.56 44.31 44.84 16.56 18.47 25.15 36.96 42.11
10 74.75 74.48 73.56 26.52 28.17 46.19 55.38 64.45
Mean 58.62 59.81 59.22 26.74 29.33 37.16 48.29 54.46
SEM 13.92 12.90 12.59 6.24 9.01 7.88 10.00 10.08
Subject FAM1 FAM2 PRE POST 1D 3D 7D 10D
11 74.14 78.27 79.80 41.32 42.42 52.27 76.65 77.97
12 46.95 50.58 50.07 16.68 21.61 29.62 37.83 45.14
13 43.55 41.50 44.66 22.25 21.75 25.76 32.76 42.36
14 44.90 51.34 51.40 32.56 29.96 39.18 49.11 53.52
15 40.21 43.76 43.79 22.31 29.61 35.63 43.02 43.43
16 39.97 41.88 42.43 15.51 18.17 23.86 33.00 36.05
17 45.89 46.86 47.38 21.97 30.30 37.30 46.81 48.98
18 40.27 37.88 37.47 13.78 17.41 22.41 32.08 32.42
19 76.54 79.03 80.21 41.61 39.50 49.45 58.97 66.45
20 60.71 63.94 63.85 31.18 35.80 47.95 58.66 59.06
21 53.24 54.68 54.14 20.28 29.91 38.94 49.14 51.03
Mean 51.49 53.61 54.11 25.40 28.77 36.58 47.09 50.58
SEM 13.31 14.32 14.54 9.83 8.36 10.41 13.74 13.32
Placebo
NAC
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MVC TORQUE STATISTICAL TABLE 
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PERCENT DECLINE IN MVC TORQUE STATISTICAL TABLE 
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MVC TORQUE DIFFERENCE BETWEEN ANGLES STATISTICAL TABLE 
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APPENDIX I 
 
RANGE OF MOTION 
(degrees of flexion) 
 
Subject PRE POST 1D 3D 7D 10D
1 121.00 96.67 115.00 115.00 120.00 120.00
2 124.00 95.00 100.00 100.00 125.00 120.00
3 120.00 93.33 108.33 100.00 122.00 120.00
4 126.00 86.67 107.00 108.00 122.33 126.00
5 132.33 106.00 105.33 117.00 123.00 129.67
6 125.67 101.00 101.33 113.67 126.33 129.00
7 125.67 95.00 102.67 116.00 120.67 119.67
8 127.33 98.67 114.33 111.00 128.33 128.67
9 136.00 101.33 109.67 118.67 133.67 135.67
10 131.33 100.67 110.67 107.33 125.67 129.67
Mean 126.93 97.43 107.43 110.67 124.70 125.83
SEM 5.02 5.36 5.17 6.72 4.10 5.62
Subject PRE POST 1D 3D 7D 10D
11 108.00 76.00 92.33 99.00 113.67 115.67
12 123.33 105.33 104.00 100.00 118.67 131.67
13 132.67 100.00 109.00 115.67 123.00 136.00
14 130.00 104.33 112.33 115.33 128.67 129.00
15 127.67 102.67 115.33 119.33 130.00 131.00
16 125.00 92.67 116.00 107.33 121.67 129.67
17 133.00 104.33 110.67 124.00 132.00 132.67
18 124.33 86.67 104.00 107.00 124.00 127.67
19 119.00 102.33 109.67 107.67 120.00 130.67
20 126.67 101.00 113.67 112.67 126.67 127.67
21 126.00 101.33 101.67 105.67 128.33 125.33
Mean 125.06 97.88 108.06 110.33 124.24 128.82
SEM 6.98 9.16 7.05 7.82 5.52 5.21
NAC
Placebo
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RANGE OF MOTION STATISTICAL TABLE 
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APPENDIX J 
VAS MUSCLE SORENESS RATING 
(mm) 
 
 
Subject PRE POST 1D 3D 7D 10D
1 1.33 8.00 38.67 87.33 21.00 8.33
2 2.33 15.67 28.00 74.33 24.33 1.00
3 3.33 11.00 42.00 76.00 12.00 11.67
4 0.00 0.00 19.00 74.00 0.00 0.00
5 0.00 9.67 21.33 75.33 30.33 0.00
6 1.33 32.33 63.67 83.00 12.67 3.00
7 0.00 4.00 19.00 67.33 14.67 0.00
8 0.00 9.00 26.00 74.00 14.33 0.00
9 0.00 10.67 22.00 56.33 12.67 0.00
10 0.00 3.67 12.33 80.33 14.33 0.00
Mean 0.83 10.40 29.20 74.80 15.63 2.40
SEM 1.21 8.89 15.13 8.53 8.17 4.19
Subject PRE POST 1D 3D 7D 10D
11 0.00 1.33 20.00 62.33 1.33 0.00
12 0.00 6.67 66.67 93.00 15.33 1.67
13 0.00 3.67 26.67 69.67 9.67 0.00
14 0.00 16.67 36.00 74.00 2.00 0.00
15 0.00 2.00 33.33 80.00 11.33 0.00
16 2.67 3.00 31.00 83.67 7.00 2.33
17 0.00 3.33 3.67 68.67 36.33 0.00
18 0.00 0.00 15.00 69.00 12.00 0.00
19 1.67 21.33 36.00 70.00 5.00 0.00
20 0.33 24.33 19.67 63.67 13.00 0.00
21 0.00 3.00 37.67 66.67 14.00 0.00
Mean 0.42 7.76 29.61 72.79 11.55 0.36
SEM 0.90 8.69 16.19 9.27 9.48 0.82
NAC
Placebo
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VAS MUSCLE STORENESS STATISTICAL TABLE 
 
 
!
 142 
APPENDIX K 
 
ARM CIRCUMFERENCE 
(cm) 
 
 
Subject PRE POST 1D 3D 7D 10D
1 25.00 25.20 25.30 25.50 25.70 25.20
2 21.00 21.10 21.30 21.50 22.10 21.30
3 24.00 24.10 24.30 24.50 25.00 24.40
4 27.80 27.85 28.00 28.33 28.50 28.00
5 27.23 27.30 27.48 27.80 28.00 27.35
6 25.80 25.90 25.98 26.17 26.40 25.95
7 40.90 41.00 41.32 41.58 41.88 41.03
8 29.47 29.58 29.67 29.70 29.97 24.62
9 22.83 22.98 23.18 23.35 23.58 22.98
10 25.55 25.65 25.72 25.88 26.27 25.67
Mean 26.96 27.07 27.23 27.43 27.74 26.65
SEM 5.48 5.47 5.50 5.52 5.48 5.42
Subject PRE POST 1D 3D 7D 10D
11 31.53 31.73 32.00 32.43 32.53 31.73
12 26.52 26.58 26.80 27.10 27.40 26.55
13 23.53 23.62 23.80 24.00 24.60 23.55
14 24.30 24.38 24.50 24.70 25.02 24.37
15 27.00 27.12 27.22 27.48 27.85 27.00
16 33.58 33.68 33.73 33.87 34.08 33.63
17 29.50 29.58 29.68 29.88 30.68 29.58
18 24.87 24.98 25.17 25.50 25.80 24.97
19 30.37 30.52 30.62 30.75 30.98 30.32
20 28.87 28.98 30.02 30.27 30.48 28.88
21 26.07 26.17 26.28 26.48 26.78 26.20
Mean 27.83 27.94 28.17 28.41 28.75 27.89
SEM 3.20 3.22 3.24 3.24 3.18 3.21
Placebo
NAC
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ARM CIRCUMFERENCE STATISTICAL TABLE 
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APPENDIX L 
 
CREATINE KINASE 
(U·L) 
 
Subject PRE 1D 3D 7D 10D
1 139.09 829.44 1490.29 123.93 27.69
2 141.73 189.68 692.16 222.32 22.74
3 28.84 89.32 924.86 18.13 65.10
4 19.12 38.56 525.05 * 34.61
5 42.52 101.02 718.86 177.65 45.32
6 107.94 113.22 549.11 145.52 54.88
7 145.68 * * * *
8 1586.69 1442.82 1967.05 891.90 48.95
9 17.47 122.94 471.82 31.64 18.95
10 27.52 149.64 334.38 67.73 41.53
Mean 225.66 341.85 852.62 209.85 39.97
SEM 481.29 477.48 537.41 284.51 15.34
Subject PRE 1D 3D 7D 10D
11 * * * * *
12 86.36 215.72 648.65 285.76 78.61
13 117.83 120.47 337.84 14.01 39.88
14 98.39 137.28 510.22 22.08 43.84
15 33.29 33.45 495.22 * 19.61
16 67.90 66.74 540.21 135.14 72.84
17 184.25 221.66 893.71 39.22 34.61
18 48.45 152.60 639.92 48.45 34.44
19 56.69 89.98 784.61 612.89 140.08
20 26.04 55.21 1620.31 39.22 22.58
21 105.97 136.45 459.96 107.44 57.35
Mean 82.52 122.96 693.07 144.91 54.38
SEM 47.22 63.65 363.58 195.00 35.92
Placebo
NAC
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CREATINE KINASE STATISTICAL TABLE 
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APPENDIX M 
 
INTERLEUKIN-6 
(pg·ml-1) 
Subject PRE 3D Subject PRE 3D
1 26.50 25.12 11 * *
2 25.47 23.06 12 23.41 28.22
3 24.78 24.78 13 26.84 27.19
4 19.63 24.78 14 27.87 23.75
5 23.06 22.72 15 26.50 23.06
6 23.75 23.41 16 21.00 20.66
7 * * 17 17.56 18.59
8 16.19 6.22 18 25.12 25.12
9 20.31 21.69 19 28.56 24.44
10 20.31 15.85 20 4.50 27.87
21 18.25 15.50
Mean 22.22 20.85
SEM 3.33 6.16 Mean 21.96 23.44
SEM 7.26 4.15
Placebo NAC
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INTERLEUKIN-6 STATISTICAL TABLE 
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APPENDIX N 
 
GLUTATHIONE 
(µM) 
 
Serum Glutathione Serum Glutathione
Subject (uM) Subject (uM)
1 3.06 11 *
2 4.28 12 2.61
3 2.65 13 3.78
4 2.55 14 2.47
5 2.56 15 2.97
6 3.22 16 3.31
7 4.96 17 3.66
8 3.58 18 4.60
9 2.87 19 3.16
10 2.09 20 3.30
21 3.16
Mean 3.18
SEM 0.88 Mean 3.30
SEM 0.61
Placebo NAC
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GLUTATHIONE STATISTICAL TABLE 
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APPENDIX O 
 
FOOD FREQUENCY QUESTIONNAIRE DATA 
 
Subject Score Subject Score
1 34.50 11 29.70
2 55.30 12 19.30
3 45.00 13 22.60
4 34.10 14 12.50
5 39.20 15 31.30
6 48.40 16 37.10
7 30.75 17 35.80
8 32.60 18 48.20
9 44.20 19 52.40
10 46.30 20 41.20
21 8.00
Mean 41.04
SEM 8.04 Mean 30.74
SEM 14.89
Placebo NAC
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APPENDIX P 
 
CALIBRATION DATA 
   
152 
ARM CALIBRATION 
(volts) 
 
 
!"# # $"# %& %!"# %# !"# # $"# %& %!"# %# !"# # $"# %& %!"# %#
'()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+ '()*"+
,-./(0123 !"## $"!% $"&' #"() )")! *"!( !"%* !"'( $")' #"!& )"++ )"(+ %"'+ !")+ $"!% $"&% #"*% )"$!
,-./(0#23 !"#) $"!! $"&' #"() )")! *"!& !"%( !"'( $"!) #"!& )"++ )"(% %"'+ !")+ $"!% $"&% #"*! )"$!
,-./(0423 !"#) $"!! $"&& #"() )")! *"!& !"%( !"'' !"&! #"!& )"++ )"(% %"'+ !")% $"!% $"&% #"*! )"$!
,-./(0$23 !"!( $"+# $"'% #")( )"$# *"%% !"++ !"(+ $"#% #"%! #"'$ )")# %"*$ !"$# $"+# $"() #"#) )"%*
,-./(0523 !"#$ $"!+ $"&( #"(# )")+ *"!( !"%) !"'* $")( #"!' #"&& )"(+ %"(' !"#' $"%& $"'& #"*+ )"$+
,-./(0%%23 !"$& $"%) $"&! #"*& )"#* *"!$ !"%% !"'! $")$ #"!$ #"&# )"*) %"(# !"#) $"%) $"'* #")* )"!(
,-./(0%!23 !"$) $"%! $"'& #"** )"#$ *"%& !"+( !"(' $"#& #"!+ #"&% )"*! %"(! !"#! $"%! $"'$ #")$ )"!#
,-./(0%623 !"#' $"!) #"+! #"(& )")* *"$! !"!+ !"&% $"*% #"$! )"+$ )"(# %"'$ !")# $"!# $"&) #"*) )"$*
,-./(0%123 !"*' $"#) #"!! #"&& )"(* *")$ !"$' $"%+ $"'% #")% )"!! )"&$ %"') !"(! $"#! #"%$ #"'$ )")#
,-./(0%#23 !"!# $"+% $"(( #")# )"$% *"+' !"+( !"*' $"$& #"%+ #"'% )")% %"(! !"$% $"+! $"(! #"#! )"%$
,-./(0%523 !"$+ $"+( $"'# #"*% )"$( *"%# !"+$ !"(# $"#) #"%) #"'* )")( %"** !"$( $"+( $"(' #"#' )"%&
,-./(0%723 !"!! !"&& $"(* #")! )"!& *"+* %"&* !"** $"$( #"+' #"(& )")+ %"*& !"$+ $"++ $"(+ #"#% )"%%
,-./(0!&23 !"!' $"+) $"'% #")' )"$) *"%! !"+% !"(% $"#! #"%$ #"'# )")) %"*# !"$) $"+) $"(* #"#* )"%(
,-./(0!%*2 !")$ $"$% #"+( #"'# )"*% *"$' !"!# !"&* $"*( #"$( )"+' )"(& %"'( !")& $"!& #"++ #"(+ )"#%
,-./(0!!89 !"$) $"%! $"'' #"*) )"#! *"%& !"+( !"(' $"#& #"!+ #"&+ )"*% %"(% !"#% $"%% $"'! #")! )"!$
,-./(0!#23 !"#+ $"%( $"&# #"(+ )"#( *"!# !"%! !"'$ $")# #"!) #"&* )"** %"() !"#* $"%* $"'( #")( )"!'
,-./(0!423 !"#) $"!! $"&& #"(* )")$ *"$+ !"%* !"'' $")& #"$+ )"++ )"(% %"'+ !")% $"!% $"&! #"*! )"$$
,-./(0!$23 !"!* $"+$ $"(& #")* )"$$ *"%+ !"+# !"(+ $"#% #"%% #"'! )")$ %"*! !"$$ $"+$ $"(# #"## )"%)
,-./(0!523 !"*) $"#$ #"!+ #"&( )"(# *")+ !"$* $"+( $"(' #"#& )"!+ )"&% %"&& !"(+ $"#% #"%% #"'! )")!
,-./(0!723 !"#) $"!$ #"++ #"(( )")$ *"$+ !"%( !"'& $"*+ #"$+ )"+% )"(! %"'+ !")! $"!! $"&! #"*$ )"$$
:;<0!89 !"$! $"+& $"'* #"*! )"$& *"%* !"+) !"(* $"#( #"%' #"'' )")& %"*' !"$& $"+& $"'+ #")+ )"!%
:;<06.9 !")% $"!' #"+) #"'! )")& *"$* !"!! !"&# $"*# #"$) )"+* )"(( %"(( !")* $"!( $"&( #"*' )"$'
:;<0123 !"*% $"$& #"%) #"&! )"*& *"#* !"$% $"+$ $"(# #"#) )"%* )"'* %"(! !"** $"$* #"+* #"(( )"#(
:;<0#23 !"#% !"&& $"(* #")! )"!& *"+* !"+) !"** $"$( #"+' #"(& )")+ %"*( !"!& $"++ $"(+ #"#% )"%%
:;<0423 !"$( $"%# $"&% #"*( )"## *"!% !"+& !"'+ $")% #"!! #"&$ )"*$ %"($ !"#$ $"%# $"'# #")) )"!)
:;<0723 !"#! $"%' $"&) #"(! )"#& *"!* !"%$ !"'# $")) #"!* #"&( )"*' %"(( !"#( $"%' $"'' #")& )"!&
:;<0%&23 !"$( $"+) $"'! #")& )"$* *"%$ !"+% !"(! $"#$ #"%# #"') )")* %"*) !"$) $"+* $"(* #"#( )"%(
:;<0%%23 !")) $"$$ #"%+ #"'( )"*$ *"#+ !"!* !"&' $"*& #"$& )"%+ )"'% %"'& !"*% $"$% #"+! #"(! )"#$
:;<0%!23 !")' $"$* #"%$ #"'& )"** *"#$ !"%& $"++ $"(% #"#! )"%$ )"'# %"(# !"*$ $"$# #"+# #"() )"#)
:;<0%623 !"$& $"+$ $"'+ #")* )"$$ *"%+ !"%+ !"(+ $"#% #"%! #"'$ )")$ %"*$ !"$$ $"+# $"(# #"#) )"%)
:=;8 !"#! $"%' $"&) #"(% )"#' *"!) !"%# !"'# $")% #"!) #"&* )"*( %"() !"#( $"%( $"'' #")' )"!&
>?: +"%! +"%$ +"%$ +"%$ +"%$ +"%$ +"%% +"%! +"%( +"%! +"%! +"%! +"+& +"%! +"%! +"%! +"%! +"%!
@A #"&# #"%' $"$* !"'! !"#! !"%! #"&# #"$# #"&( !"'& !"#' !"%( #"&* #"&% $"'! $"%$ !"*) !"!&
BC*/DC80! BC*/DC806 BC*/DC801
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LOAD CELL CALIBRATION 
 
RAW DATA AND DAILY COEFFICIENT OF VARIATION 
(volts) 
 
 
Load Mean Standard CV Mean Standard CV Mean Standard CV
(lbs) (volts) Deviation (%) (volts) Deviation (%) (volts) Deviation (%)
2.5 2.1964 0.0012 0.05 2.1885 0.0001 0.01 2.2103 0.0003 0.01
5 2.8134 0.0005 0.02 2.8029 0.0004 0.01 2.7930 0.0002 0.01
7.5 3.4244 0.0003 0.01 3.3687 0.0009 0.03 3.4075 0.0007 0.02
10 3.9903 0.0002 0.01 4.0361 0.0006 0.01 4.0456 0.0018 0.04
12.5 4.6294 0.0010 0.02 4.6208 0.0007 0.02 4.6220 0.0002 0.00
15 5.2886 0.0002 0.00 5.2698 0.0014 0.03 5.2710 0.0011 0.02
2.5 2.1244 0.0005 0.02 2.1231 0.0006 0.03 2.1211 0.0005 0.02
5 2.7244 0.0010 0.04 2.7256 0.0005 0.02 2.7366 0.0000 0.00
7.5 3.2991 0.0007 0.02 3.3077 0.0004 0.01 3.3019 0.0002 0.01
10 3.9278 0.0006 0.01 3.8994 0.0003 0.01 3.9266 0.0003 0.01
12.5 4.4897 0.0009 0.02 4.5165 0.0004 0.01 4.5061 0.0002 0.00
15 5.1852 0.0014 0.03 5.1617 0.0003 0.00 5.1774 0.0005 0.01
2.5 2.0213 0.0003 0.01 2.0353 0.0003 0.01 2.0460 0.0016 0.08
5 2.6000 0.0008 0.03 2.6270 0.0002 0.01 2.6406 0.0003 0.01
7.5 3.1775 0.0004 0.01 3.1944 0.0003 0.01 3.2221 0.0002 0.01
10 3.8019 0.0004 0.01 3.8001 0.0002 0.00 3.8213 0.0007 0.02
12.5 4.3356 0.0016 0.04 4.3926 0.0052 0.12 4.3892 0.0008 0.02
15 4.9803 0.0010 0.02 5.0367 0.0007 0.01 5.0380 0.0012 0.02
2.5 1.9859 0.0051 0.26 1.9672 0.0108 0.55 1.9705 0.0007 0.03
5 2.6121 0.0029 0.11 2.5803 0.0011 0.04 2.5814 0.0015 0.06
7.5 3.1848 0.0061 0.19 3.1490 0.0008 0.02 3.1523 0.0011 0.04
10 3.7927 0.0043 0.11 3.7355 0.0029 0.08 3.7579 0.0008 0.02
12.5 4.3310 0.0015 0.03 4.3242 0.0009 0.02 4.3044 0.0003 0.01
15 4.9371 0.0027 0.05 4.9841 0.0017 0.03 4.9561 0.0011 0.02
2.5 2.0509 0.0010 0.05 2.0303 0.0001 0.01 2.0425 0.0002 0.01
5 2.6332 0.0013 0.05 2.6333 0.0002 0.01 2.6186 0.0006 0.02
7.5 3.2132 0.0028 0.09 3.2142 0.0009 0.03 3.1763 0.0001 0.00
10 3.7647 0.0037 0.10 3.7793 0.0005 0.01 3.7989 0.0001 0.00
12.5 4.3735 0.0027 0.06 4.3891 0.0006 0.01 4.3789 0.0005 0.01
15 4.9899 0.0016 0.03 5.0055 0.0008 0.02 5.0376 0.0014 0.03
2.5 2.0448 0.0007 0.04 2.0302 0.0005 0.03 2.0294 0.0003 0.02
5 2.6583 0.0016 0.06 2.6370 0.0001 0.00 2.6505 0.0003 0.01
7.5 3.2367 0.0020 0.06 3.2254 0.0004 0.01 3.1877 0.0002 0.01
10 3.8174 0.0027 0.07 3.8538 0.0003 0.01 3.8579 0.0008 0.02
12.5 4.4273 0.0023 0.05 4.3977 0.0014 0.03 4.3959 0.0014 0.03
15 5.0973 0.0018 0.04 5.0985 0.0005 0.01 5.0479 0.0012 0.02
2.5 1.9782 0.0004 0.02 1.9510 0.0002 0.01 1.9753 0.0003 0.01
5 2.5557 0.0010 0.04 2.5763 0.0003 0.01 2.5811 0.0009 0.03
7.5 3.1177 0.0016 0.05 3.1556 0.0008 0.02 3.1552 0.0004 0.01
10 3.7365 0.0025 0.07 3.7491 0.0003 0.01 3.7629 0.0003 0.01
12.5 4.3208 0.0019 0.04 4.3419 0.0009 0.02 4.2753 0.0003 0.01
15 4.9363 0.0021 0.04 4.9826 0.0011 0.02 4.9481 0.0009 0.02
TRIAL 1 TRIAL 2 TRIAL 3
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LOAD CELL CALIBRATION 
 
DAILY COEFFICIENT OF VARIATION BETWEEN LOADS 
 
Load Mean Standard CV
(lbs) (volts) Deviation (%)
2.5 2.1984 0.0111 0.50
5 2.8031 0.0102 0.36
7.5 3.4002 0.0286 0.84
10 4.0240 0.0296 0.73
12.5 4.6241 0.0046 0.10
15 5.2765 0.0105 0.20
2.5 2.1229 0.0017 0.08
5 2.7289 0.0067 0.25
7.5 3.3029 0.0044 0.13
10 3.9179 0.0161 0.41
12.5 4.5041 0.0135 0.30
15 5.1748 0.0120 0.23
2.5 2.0342 0.0124 0.61
5 2.6225 0.0207 0.79
7.5 3.1980 0.0225 0.70
10 3.8078 0.0118 0.31
12.5 4.3725 0.0320 0.73
15 5.0183 0.0329 0.66
2.5 1.9745 0.0100 0.51
5 2.5913 0.0180 0.70
7.5 3.1620 0.0198 0.63
10 3.7620 0.0288 0.77
12.5 4.3199 0.0138 0.32
15 4.9591 0.0236 0.48
2.5 2.0413 0.0104 0.51
5 2.6284 0.0084 0.32
7.5 3.2012 0.0216 0.67
10 3.7810 0.0172 0.45
12.5 4.3805 0.0079 0.18
15 5.0110 0.0243 0.49
2.5 2.0348 0.0086 0.42
5 2.6486 0.0108 0.41
7.5 3.2166 0.0257 0.80
10 3.8430 0.0223 0.58
12.5 4.4070 0.0176 0.40
15 5.0812 0.0289 0.57
2.5 1.9681 0.0149 0.76
5 2.5710 0.0135 0.53
7.5 3.1428 0.0218 0.69
10 3.7495 0.0132 0.35
12.5 4.3127 0.0340 0.79
15 4.9556 0.0241 0.49
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LOAD CELL CALIBRATION 
 
COEFFICIENT OF VARIATION BETWEEN DAYS 
 
 
 
 
 
 
Load Mean Standard CV
(lbs) (volts) Deviation (%)
2.5 2.0535 0.0819 3.99
5 2.6562 0.0819 3.09
7.5 3.2320 0.0899 2.78
10 3.8407 0.0989 2.58
12.5 4.4172 0.1112 2.52
15 5.0681 0.1192 2.35
